microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft united states personal investing trowepricecom personal investing workplace retirement institutional investor institutional consultant financial advisorintermediary recordkeeping sponsorconsultant log out log in open an account about us help my accounts portfolio transactions statements  documents profile mutual funds daily prices historical performance dividend distributions mutual fund research tool morningstar  and star rated funds stock funds bond funds target date funds asset allocation funds money market funds prospectuses  reports retirement ira rollover ira retirement planning required minimum distributions small business retirement plans b plans planning  research advice investing  asset allocation planning retirement planning college planning tax planning estate planning research  analysis t rowe price insights planning  resources charitable giving products  services activeplus portfolios college savings plans non retirement accounts private asset management select client services advisory planning services brokerage investor centers t rowe price value fund trvlx home  mutual funds t rowe price value fund print this page email this page text size new quarterly fund fact sheet now available ticker symbol trvlx fund status open to new retail investors    open to subsequent retail investments snapshot objective performance composition management expensesminimums compare fund snapshot quick stats current nav as of   nav change  daily ytd return as of   nav  month lowhigh    net assets as of   million morningstar ratings as of  overall  year  year  year morningstar rated the value fund among    and  large value funds for the overall rating and the   and year periods as applicable ending  respectively the overall morningstar rating for a managed product is derived from a weighted average of the performance figures associated with its three five and year if applicable morningstar rating metrics the weights are  threeyear rating for  months of total returns  fiveyear rating threeyear rating for  months of total returns and  year rating fiveyear rating threeyear rating for  or more months of total returns while the year overall star rating formula seems to give the most weight to the year period the most recent threeyear period actually has the greatest impact because it is included in all three rating periods performance comparison as of  this chart shows the value of a hypothetical  investment in the fund over the past  years or since its inception for funds lacking year records the result is compared with benchmarks which may include a broadbased market index and a peer group average or index market indexes do not include expenses which are deducted from fund returns as well as mutual fund averages and indexes benchmark definitions  the morningstar rating for funds or star rating is calculated for managed products including mutual funds variable annuity and variable life subaccounts exchangetraded funds closedend funds and separate accounts with at least a threeyear history exchangetraded funds and openended mutual funds are considered a single population for comparative purposes it is calculated based on a morningstar riskadjusted return measure that accounts for variation in a managed products monthly excess performance placing more emphasis on downward variations and rewarding consistent performance the top  of products in each product category receive  stars the next  receive  stars the next  receive  stars the next  receive  stars and the bottom  receive  star the overall morningstar rating for a managed product is derived from a weighted average of the performance figures associated with its three five and year if applicable morningstar rating metrics the weights are  threeyear rating for  months of total returns  fiveyear rating threeyear rating for  months of total returns and  year rating fiveyear rating threeyear rating for  or more months of total returns while the year overall star rating formula seems to give the most weight to the year period the most recent threeyear period actually has the greatest impact because it is included in all three rating periods source for morningstar data   morningstar inc all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information past performance is no guarantee of future results average annual total returns and benchmarks as of  benchmark definitions investment objective the fund seeks to provide longterm capital appreciation by investing in common stocks believed to be undervalued income is a secondary objective average annual total returns    monthend  quarterend   year    years    years    years   since inception   inception date september   gross expense ratio  net expense ratio  waiver type na limitation expires na current performance may be lower or higher than the quoted past performance which cannot guarantee future results share price principal value and return will vary and you may have a gain or loss when you sell your shares  average annual total return figures include changes in principal value reinvested dividends and capital gain distributions for funds less than one year old the since inception return figure is not annualized and represents an aggregate total return  the gross expense ratio reflects the fund expenses as stated in the fee table of the funds prospectus prior to the deduction of any waiver or reimbursement the net expense ratio reflects fund expenses after the deduction of any waiver or reimbursement if a fund has an active contractual expense ratio limitation the expiration date is shown below the gross and net expense ratio values above expense ratios are as of the most recent prospectus open an account transact  trade viewupdate accounts help center find a fund select fund by name africa  middle east  i cl africa  middle east fund asia opportunities asia opportunities  i cl balanced balanced  i cl blue chip growth blue chip growth  i cl california taxfree bond california taxfree bond  i cl california taxfree money california taxfree money  i cl capital appreciation capital appreciation  i cl capital opportunity capital opportunity  i cl cash reserves corporate income corporate income  i cl credit opportunities credit opportunities  i cl diversified midcap growth diversified midcap growth  i cl dividend growth dividend growth  i cl dynamic global bond dynamic global bond  i cl em mkts corporate bond  i cl em mkts local currency bond  i cl emerging europe emerging europe  i cl emerging markets bond emerging markets bond  i cl emerging markets corporate bond emerging markets local currency bond emerging markets stock emerging markets stock  i cl emerging markets value stock emerging markets value stock  i cl equity income equity income  i cl equity index  equity index   i cl european stock european stock  i cl extended equity market index financial services financial services  i cl floating rate floating rate  i cl georgia taxfree bond georgia taxfree bond  i cl global allocation global allocation  i cl global consumer global growth stock global growth stock  i cl global high income bond global high income bond  i cl global industrials global industrials  i cl global multisector bond global multisector bond  i cl global real estate  i cl global real estate fund global stock global stock  i cl global technology  i cl global technology fund gnma gnma  i cl government money government money  i cl growth  income growth  income  i cl growth stock growth stock  i cl health sciences health sciences  i cl high yield high yield  i cl inflation protected bond inflation protected bond  i cl intermediate taxfree high yield intermediate taxfree hy  i cl international bond international bond  i cl international concentrated eq  i cl international concentrated equity international discovery international discovery  i cl international equity index international stock international stock  i cl international value equity international value equity  i cl japan japan  i cl latin america latin america  i cl limited duration inflation focused bd lmtd duration infl focused bd  i cl maryland shortterm taxfree bond maryland shortterm txfr bnd  i cl maryland taxfree bond maryland taxfree bond  i cl maryland taxfree money maryland taxfree money  i cl media  telecommunications media  telecommunications  i cl midcap growth midcap growth  i cl midcap value midcap value  i cl new america growth new america growth  i cl new asia new asia  i cl new era new era  i cl new horizons new horizons  i cl new income new income  i cl new jersey taxfree bond new jersey taxfree bond  i cl new york taxfree bond new york taxfree bond  i cl new york taxfree money new york taxfree money  i cl overseas stock  i cl overseas stock fund personal strategy balanced personal strategy balanced  i cl personal strategy growth personal strategy growth  i cl personal strategy income personal strategy income  i cl qm global equity qm global equity  i cl qm us small  midcap core eq  i cl qm us small  midcap core equity qm us smallcap growth equity qm us smallcap growth equity  i cl qm us value equity qm us value equity  i cl real assets real assets  i cl real estate real estate  i cl retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement balanced fund retirement balanced i  i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement income  science  technology science  technology  i cl shortterm bond shortterm bond  i cl smallcap stock smallcap stock  i cl smallcap value smallcap value  i cl spectrum growth spectrum income spectrum international summit municipal income summit municipal intermediate summit municipal money market target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl taxefficient equity  i cl taxefficient equity fund taxexempt money taxexempt money  i cl taxfree high yield taxfree high yield  i cl taxfree income taxfree income  i cl taxfree shortintermediate taxfree shortintermediate  i cl total equity market index total return total return  i cl us bond enhanced index us high yield us high yield  i cl us largecap core  i cl us largecap core fund us treasury intermediate us treasury intermediate  i cl us treasury longterm us treasury longterm  i cl us treasury money us treasury money  i cl ultra shortterm bond ultra shortterm bond  i cl value value  i cl virginia taxfree bond virginia taxfree bond  i cl select by ticker symbol gtfbx mdxbx njtfx nytxx otcfx otiix pbdix pccox pctxx pdgix pexmx pglox pgmsx pgtix pieqx pnaix pnsix pomix ppipx prafx pramx prasx prcix prcnx prcox prcpx prdgx prdmx prdsx prefx preix prelx premx presx prfdx prfhx prfrx prfsx prgfx prgix prgmx prgsx prgtx prhix prhsx prhyx pridx prihx prijx prikx prinx pripx prisx pritx priux prjix prjpx prkix prlax prmdx prmsx prmtx prnex prnhx prnyx prpix prrxx prscx prsgx prsix prsmx prsnx prsvx prtax prtix prtxx prufx pruix prulx pruux prvax prvix prwax prwbx prwcx prxax prxcx prxex prxix przix psilx ptexx ptkix pttfx ptyix rbaix rclix reipx revix rggix ricix rjaix rlaix rpbax rpeix rpgax rpgex rpgix rpgrx rpibx rpiex rpihx rpisx rpmgx rpoix rpsix rptfx rptix rpttx tbcix tbgax tbsix tcbxx tcfex tcrrx tecix teefx teimx terxx teuix tfaix tfbix tfbvx tfhax tfifx tfilx tfrrx tgafx tgipx tgtix thisx ticcx tiddx tiipx tirgx tirrx tmdxx toorx torfx tpgpx tppax tqaix tqgex tqgix tqmvx tqsix tqsmx tqvix traix tramx traox trarx trasx trbcx trbfx trbrx trbux trecx tremx trffx trfgx trfox trfwx trgax trglx trgrx trgxx trhrx trigx trjix trlax trldx trmcx trmix trmux trnex trnxx troix trosx trpax trpbx trpcx trpdx trpfx trphx trpix trpjx trpkx trplx trpmx trpnx trppx trptx trrax trrbx trrcx trrdx trrex trrfx trrgx trrhx trrix trrjx trrkx trrlx trrmx trrnx trrox trrtx trrux trrvx trrwx trsgx trstx trsxx trtfx trtix trulx trvlx trvvx trxrx tryix tscxx tsnix tteex ttgxx ttmix ttoix ttrtx ttsix tturx tuhix tuhyx twnxx twrrx more fund information download a prospectus download a semiannual report download an annual report download statement of additional information yearend dividend distributions yearend tax considerations dividend distribution dates   related links also available to certain investors as a lower cost i class mutual fund our mission is simple help clients around the world achieve their longterm investment goals connect with us facebook twitter youtube linkedin company overview responsibility careers investor relations press releases site map privacy policy terms of use security measures legal information customer agreement feedback mobile solutions contact us the mutual funds referred to in this website are offered and sold only to persons residing in the united states and are offered by prospectus only the prospectuses include investment objectives risks fees expenses and other information that you should read and consider carefully before investing download a prospectus  all rights reserved t rowe price investment services inc distributor t rowe price mutual funds t rowe price invest with confidence and the bighorn sheep design are trademarks of t rowe price group inc all other trademarks are the property of their respective owners morningstar  and star rated funds  mutual funds  t rowe price  t rowe price home mutual funds morningstar  and star rated funds over  of our funds have earned  or star overall morningstar ratings as of  invest now call us at  download a prospectus morningstar  and star rated funds stock funds us stock funds international and global stock funds bond funds us bond funds international and global bond funds target date funds retirement funds target funds income funds asset allocation funds money market funds find a fund browse all t rowe price mutual funds many of our mutual funds earn morningstar’s highest ratings morningstar  and star rated funds because of our disciplined approach to investing morningstar a leader in independent investment research recognizes many of our mutual funds with its highest ratings in the funds respective categories over  of our funds have earned  or star overall morningstar ratings as of  morningstar uses a star system to rate mutual funds based on their riskadjusted returns five stars is the highest while one star is the lowest rating only the top  of all funds of the   get  stars and  get  stars are awarded morningstars  or star rating by comparison as of   of  of our rated funds investor class only received an overall rating of  or  stars​ past performance cannot guarantee future results view all  and star rated funds explore morningstar  and star rated funds fund nameticker morningstarcategory overall morningstarrating™ no offunds incategory riskrewardpotential fund name ticker morningstar category overall morningstar rating™ no of funds in category riskreward potential compare morningstar  and star rated funds find a fund browse all t rowe price mutual funds t rowe price insightsreg markets  economy monthly market review stay informed about global economic developments and our perspective on market conditions read more   source t rowe price markets  economy global markets weekly update keep uptodate on our views on developments in global capital markets read more july    source t rowe price all mutual funds are subject to market risk including possible loss of principal morningstar gives its best ratings of  or  stars to the top  of all funds of the   get  stars and  get  stars based on their riskadjusted returns the overall morningstar rating™ is derived from a weighted average of the performance figures associated with a funds   and year if applicable morningstar rating™ metrics as of   of  of our rated funds investor class only received an overall rating of  or  stars the morningstar ratingtm for funds or star rating is calculated for funds with at least a threeyear history exchangetraded funds and openended mutual funds are considered a single population for comparative purposes it is calculated based on a morningstar riskadjusted return measure that accounts for variation in a managed products monthly excess performance placing more emphasis on downward variations and rewarding consistent performance the top  of products in each product category receive  stars the next  receive  stars the next  receive  stars the next  receive  stars and the bottom  receive  star source for morningstar data  morningstar inc all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information past performance is no guarantee of future results this chart displays relative risk of each us mutual fund listed using standard deviation of returns those values are provided in the bars at the top of the chart methodology we evaluate the standard deviation and its resulting placement within a specific riskreturn category on an annual basis a fund is generally placed in a riskreturn category based on the year standard deviation of its performance if a fund is less than  years old the actual fund performance history is supplemented with the primary prospectus benchmark history to obtain a full year history or longest time period available up to  years for an asset allocation fund with less than  years of performance history substrategy returns are used when a substrategy is less than  years old the actual substrategy performance history is supplemented with benchmark history to obtain a full year history or longest time period available up to  years risk return categories overlap a fund with a standard deviation in the overlap between two categories denoted by a plus  is placed so that its risk categorization is better aligned with anticipated return characteristics an investor may experience going forward at the discretion of t rowe price when a fund has a cashlike benchmark denoted by a double plus  its standard deviation is estimated using only available fund returns if the fund is less than  years old benchmark returns are not used to obtain a full year history because they would artificially suppress the volatility estimate all investments are subject to market risk including the possible loss of principal standard deviation of returns a measure of price volatility is one measure of risk please consult the funds’ prospectuses for a more complete discussion of the funds’ risks  california taxfree money fund capital appreciation fund equity income fund global allocation fund global industrials fund gnma fund inflation protected bond fund international bond fund international stock fund japan fund limited duration inflation focused bond fund new era fund personal strategy balanced fund personal strategy income fund qm global equity fund qm global equity fund qm us value equity fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund shortterm bond fund spectrum international fund summit municipal intermediate fund target  fund target  fund target  fund target  fund target  fund taxfree shortintermediate fund total equity market index fund ultra shortterm bond fund  global unconstrained bond fund  page not found page not found we apologize for any inconvenience but we are unable to locate the page you requested this could be due to either of the reasons below if you manually entered the url please make sure it is correct check that the capitalization matches that all words are spelled correctly and that all the punctuation like periods  and slashes  are correctly placed be sure that you are using the forward slash  and not the backward slash  remember there are no spaces in urls if you have bookmarked this page this page may have been renamed moved or deleted please return to our homepage and reset your bookmarks mutual funds retirement and investment services  t rowe price  home mutual funds retirement and investment services introducing t rowe price®  activeplus portfolios save time with a diversified portfoliopowered by our experts get started my account   remember user name log in log in forgot user name register for online access  open an account mutual funds we offer over  noload mutual funds to address your specific investing needs see all mutual funds rollover iras changing jobs or planning for retirement our specialists make rolling over your k account easy learn more ira plan for retirement with the help of a roth ira or traditional ira learn more see all products and services   find lowcost mutual funds to help you achieve your financial goals search mutual funds  noload mutual funds providing a broad set of opportunities historical performance daily prices download a prospectus mutual fund categories we offer a full range of investment strategies across multiple asset classes capitalizations sectors and styles fund type number available stock funds  asset allocation funds  money market funds  target date funds  bond funds  see all mutual funds   over  of our mutual funds beat their year lipper average as of  learn more   t rowe price insights® access our latest investment thinking information on retirement planning and perspectives on the markets asset allocation an inside look at t rowe price® activeplus portfolios july   retirement planning  key ingredients for retirement planning july   markets  economy quarterly market review june   see all articles   ready to get started open an account or call  view firms background on finras brokercheck t rowe price mutual funds are subject to ongoing management fees and may be subject to redemption fees an ira may be subject to an annual fee and a fee may be assessed when an ira is closed see prospectus for details the mutual funds referred to in this website are offered and sold only to persons residing in the united states and are offered by prospectus only the prospectuses include investment objectives risks fees expenses and other information that you should read and consider carefully before investing morningstar gives its best ratings of  or  stars to the top  of all funds of the   get  stars and  get  stars based on their riskadjusted returns the overall morningstar rating™ is derived from a weighted average of the performance figures associated with a funds   and year if applicable morningstar rating™ metrics as of   of  of our rated funds investor class only received an overall rating of  or  stars the morningstar ratingtm for funds or star rating is calculated for funds with at least a threeyear history exchangetraded funds and openended mutual funds are considered a single population for comparative purposes it is calculated based on a morningstar riskadjusted return measure that accounts for variation in a managed products monthly excess performance placing more emphasis on downward variations and rewarding consistent performance the top  of products in each product category receive  stars the next  receive  stars the next  receive  stars the next  receive  stars and the bottom  receive  star source for morningstar data  morningstar inc all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information past performance is no guarantee of future results  of our  mutual funds had a year track record as of  includes all share classes and excludes funds used in insurance products  of these  funds beat their lipper averages for the year period  of    of   of   of t rowe price funds outperformed their lipper average for the   and year periods ended  respectively calculations are based on cumulative total return not all funds outperformed for all periods source for data lipper inc  of our  retirement funds had a year track record as of  includes all share classes  of these  funds beat their lipper averages for the year period  of   of  and  of  of the retirement funds outperformed their lipper average for the   and year periods ended  respectively calculations are based on cumulative total return not all funds outperformed for all periods source for data lipper inc source lipper inc  of  funds excluding institutional and bank institutional funds as defined by lipper more than  months old had expense ratios below their lipper averages based on fiscal yearend data available as of  the principal value of the retirement funds is not guaranteed at any time including at or after the target date which is the approximate year an investor plans to retire assumed to be age  and likely stop making new investments in the fund if an investor plans to retire significantly earlier or later than age  the funds may not be an appropriate investment even if the investor is retiring on or near the target date the funds’ allocations among a broad range of underlying t rowe price stock and bond funds will change over time the funds emphasize potential capital appreciation during the early phases of retirement asset accumulation balance the need for appreciation with the need for income as retirement approaches and focus on supporting an income stream over a longterm postretirement withdrawal horizon the funds are not designed for a lumpsum redemption at the target date and do not guarantee a particular level of income the funds maintain a substantial allocation to equities both prior to and after the target date which can result in greater volatility over shorter time horizons x you are using an unsupported browser version that might prevent you from accessing certain features on our site   we suggest clicking an icon below to download a supported browser version     google chrome mozilla firefox internet explorer safari roth or traditional ira  t rowe price home retirement ira roth or traditional ira roth or traditional ira compare roth and traditional iras roth ira traditional ira roth or traditional ira rollover and transfer iras navigate to roth ira traditional ira roth or traditional ira rollover and transfer iras when it comes to making a thoughtful decision between a roth ira and a traditional ira it helps to understand the differences   roth ira traditional ira taxes contributions made are not deductible contributions made can be taxdeductible or nondeductible deductibility of contributions depends on active participation in a retirement plan and your modified adjusted gross income magi not exceeding certain amounts withdrawal of contributions withdraw anytime without taxes or penalties withdraw anytime but deductible contributions are taxable and generally subject to penalties if withdrawn before age ½ withdrawal of earnings tax and penaltyfree when withdrawn at age ½ if account has been active for at least five years taxable when withdrawn and generally subject to penalties if withdrawn before age ½ age restrictions none   must be under age ½ during the tax year of the contribution eligibility may contribute only if depending on filing status magi does not exceed certain amounts you must have us earned income no restrictions on contributions you must have us earned income   required minimum distributions rmds none during your lifetime must begin taking for the year in which you reach age ½ ready to start call  open a roth ira open a traditional ira still unsure about roth vs traditional answer four questions to find out which ira may be right for you why t rowe price for a roth or traditional ira low fees and minimums   you need to maximize your return potential so we work to keep our fees competitive thats why our solutions include noload mutual funds with low expense ratios keep in mind that a traditional iraroth ira may be subject to an annual fee and a fee may be assessed when a traditional iraroth ira is closed heres more information on fees convenient and flexible fund choices   you can choose from target date funds with strategic asset allocation and diversification or select from more than  mutual funds to suit your investing needs download a prospectus a global investing network in pursuit of your goals   our highly tenured global investment professionals are continuously assessing potential risk while identifying opportunities to maximize growth potential over the long term so you have more money in retirement  want to move existing savings into a roth ira roll over a k a rollover ira is one of several options to consider for your former workplace retirement plan such as a k   explore your options roll over now   transfer an existing ira if you decide to transfer an ira we offer over  mutual funds from which to choose and we make it easy by handling most of the paperwork too transfer an ira now convert your t rowe price traditional ira to a roth ira a roth ira offers many advantages over a traditional ira like potentially taxfree withdrawals if you need them convert now biotech bull  bear x etf  labu labd  direxion brzu daily msci brazil bull x shareschad daily csi  china a share bear x shareschau daily csi  china a share bull x sharesclaw daily homebuilders  supplies bear x sharescom direxion auspice broad commodity strategy etfcure daily healthcare bull x sharescweb daily csi china internet index bull x sharesdfen daily aerospace  defense bull x sharesdpk daily msci developed markets bear x sharesdpst daily regional banks bull x sharesdrip daily sp oil  gas exp  prod bear x sharesdrn daily msci real estate bull x sharesdrv daily msci real estate bear x sharesdull daily silver miners index bear x sharesdusl daily industrials bull x sharesdust daily gold miners index bear x sharesdxcbx direxion indexed cvt strategy funddxcix direxion indexed commodity strategy fund – instdxctx direxion indexed commodity strategy fund – adxelx monthly emerging markets bull x funddxhlx monthly china bull x funddxhyx monthly high yield bull x funddxklx monthly  year treasury bull x funddxksx monthly  year treasury bear x funddxltx monthly  year treasury bull x funddxmax direxion indexed managed futures strategy fund – adxmcx direxion indexed managed futures strategy fund – cdxmix direxion indexed managed futures strategy fund – instdxnlx monthly nasdaq bull x funddxnsx monthly nasdaq bear x funddxqlx monthly nasdaq bull x funddxrlx monthly small cap bull x funddxrsx monthly small cap bear x funddxscx direxion indexed commodity strategy fund – cdxslx monthly sp  bull x funddxssx monthly sp  bear x funddxstx monthly  year treasury bear x funddzk daily msci developed markets bull x sharesedc daily msci emerging markets bull x sharesedz daily msci emerging markets bear x shareserx daily energy bull x sharesery daily energy bear x shareseryy daily energy bear x shareseufl daily msci european financials bull x shareseufs daily msci european financials bear x shareseurl daily ftse europe bull x shareseuxl daily euro stoxx  bull x sharesfas daily financial bull x sharesfaz daily financial bear x sharesfazz daily financial bear x sharesgasl daily natural gas related bull x sharesgasx daily natural gas related bear x sharesgush daily sp oil  gas exp  prod bull x shareshakk daily cyber security  it bull x shareshcyax direxion hilton tactical income fund – a shareshcycx direxion hilton tactical income fund – c shareshcyix direxion hilton tactical income fund – institutionalhydd daily high yield bear x sharesibln direxion ibillionaire index etfindl daily msci india bull x sharesjdst daily junior gold miners index bull x sharesjdst daily junior gold miners index bear x sharesjpnl daily msci japan bull x sharesknow direxion all cap insider sentiment shareskoru daily msci south korea bull x shareslabd daily sp biotech bear x shareslabs daily sp biotech bear x shareslabu daily sp biotech bull x shareslbj daily latin america bull x sharesllsc daily small cap bull x sharesllsp daily sp  bull x sharesmelt daily gold miners index bear x sharesmexx daily msci mexico bull x sharesmidu daily mid cap bull x sharesmidz daily mid cap bear x sharesnail daily homebuilders  supplies bull x sharesnugt daily gold miners index bull x sharespemvx evolution managed fundsqqqe direxion nasdaq equal weighted index sharesretl daily retail bull x sharesrusl daily russia bull x sharesruss daily russia bear x sharessagg daily total bond market bear x sharesshny daily silver miners index bull x sharessick daily healthcare bear x sharessmll daily small cap bull x sharessoxl daily semiconductor bull x sharessoxs daily semiconductor bear x sharesspdn daily sp  bear x sharessplz daily consumer staples bear x sharesspuu daily sp  bull x sharesspxl daily sp  bull x sharesspxs daily sp  bear x sharestecl daily technology bull x sharestecs daily technology bear x sharestecz daily technology bear x sharestmf daily  year treasury bull x sharestmv daily  year treasury bear x sharestna daily small cap bull x sharestpor daily transportation bull x sharestybs daily  year treasury bear x sharestyd daily  year treasury bull x sharestyns daily  year treasury bear x sharestyo daily  year treasury bear x sharestza daily small cap bear x sharesutlz daily utilities bear x sharesutsl daily utilities bull x shareswdrw daily regional banks bear x sharesyang daily ftse china bear x sharesyinn daily ftse china bull x shareszmlp direxion zacks mlp high income index shares direxion daily sp biotech bull and bear x shares fund symbol labu daily target  intraday indicative value labuiv bloomberg index spsibitr cusip k isin usk expense ratio grossnet     inception date may   fund symbol labd daily target  intraday indicative value labdiv bloomberg index spsibitr cusip k isin usk expense ratio grossnet     inception date may   overview the direxion daily sp biotech bull and bear x shares seek daily investment results before fees and expenses of  or  of the inverse or opposite of the performance of the sp biotechnology select industry index there is no guarantee the funds will meet their stated investment objectives these leveraged etfs seek a return that is  or  of the return of their benchmark index for a single day the funds should not be expected to provide three times or negative three times the return of the benchmark’s cumulative return for periods greater than a day labu labd fact sheet etf guide labu prospectus labd prospectus premium discount daily holdings download labu daily holdings csv download labd daily holdings csv daily holdings labu     daily sp biotech bull x shares trade date     shares outstanding  stock ticker security description shares price market value — bank of new york cash reserve    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — goldman finl sq trsry inst     — goldman finl sq trsry inst     — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    xbi spdr sp biotech etf    labd     daily sp biotech bear x shares trade date     shares outstanding  stock ticker security description shares price market value — bank of new york cash reserve    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — goldman finl sq trsry inst     — goldman finl sq trsry inst     — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    strategy  benefits key benefits you know that trading is different than investing but the opportunity to take advantage of shortterm trends is only won if you get the direction right whether you’re a bull or a bear direxion is with you our leveraged etfs are powerful tools built to help you magnify your shortterm perspective with daily x leverage go where there’s opportunity with bull and bear funds for both sides of the trade and stay agile – with liquidity to trade through rapidly changing markets leveraged and inverse etfs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage they seek daily goals and should not be expected to track the underlying index over periods longer than one day they are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments target index the sp biotechnology select industry index spsibitr is provided by standard  poor’s and includes domestic companies from the biotechnology industry the index is designed to measure the performance of the biotechnology subindustry based on the global industry classification standards gics one cannot directly invest in an index index top ten holdings  clovis oncology inc  exelixis inc  kite pharma inc  alexion pharmaceuticals inc  celgene corp  alnylam pharmaceuticals inc  gilead sciences inc  sarepta therapeutics inc  bioverativ inc  exact sciences corp  index sector weightings  medicalbiomedicalgenetics  medicaldrugs  therapeutics  medicalgeneric drugs  diagnostic kits  medical products  diagnostic equipment  drug delivery systems  index data as of  source bloomberg index sector weightings and top holdings are subject to change tax reporting supplemental tax documents  – ordinary income from us government obligations labd pricing and performance pricing and performance nav and market price information as of july   line chart shows pricing trend over the last  days fund symbol labu net asset value nav  nav   change   change  market price closing  market   change   change  premium  discount   change from last day trading fund symbol labd net asset value nav  nav   change   change  market price closing  market   change   change  premium  discount   change from last day trading monthly quarterly as of june   as of june   labu daily sp biotech bull x shares m  m  ytd  y  since inception inception date expense ratio  gross  net  m  m  ytd  y  since inception inception date expense ratio  gross  net  nav          market close      nav          market close      spsibitr benchmark index        labd daily sp biotech bear x shares m  m  ytd  y  since inception inception date expense ratio  gross  net  m  m  ytd  y  since inception inception date expense ratio  gross  net  nav          market close      nav          market close      spsibitr benchmark index         the net expense ratio includes management fees other operating expenses and acquired fund fees and expenses if acquired fund fees and expenses were excluded the net expense ratio would be  the funds’ adviser rafferty asset management llc “rafferty” has entered into an operating expense limitation agreement with each fund under which rafferty has contractually agreed to cap all or a portion of its management fee andor reimburse each fund for other expenses through september   to the extent that the fund’s total annual fund operating expenses exceed  of the fund’s daily net assets other than the following taxes swap financing and related costs acquired fund fees and expenses dividends or interest on short positions other interest expenses brokerage commissions and extraordinary expenses if these expenses were included the expense ratio would be higher the performance data quoted represents past performance past performance does not guarantee future results the investment return and principal value of an investment will fluctuate an investor’s shares when redeemed may be worth more or less than their original cost current performance may be lower or higher than the performance quoted returns for performance under one year are cumulative not annualized for the most recent monthend performance please visit the funds website at direxioninvestmentscom shortterm performance in particular is not a good indication of the fund’s future performance and an investment should not be made based solely on returns because of ongoing market volatility fund performance may be subject to substantial shortterm changes for additional information see the fund’s prospectus distributions distributions labu daily sp biotech bull x shares there are no recent distributions available for this fund labd daily sp biotech bear x shares there are no recent distributions available for this fund related reading knowledge related education articles and insights etf market pricing etf market prices are the prices at which investors buy or sell shares of an etf in the secondary market while etfs are designed to trade in line with their intraday values during times of significant market volatility an etf’s market price may vary more widely from its intraday value etf liquidity – four rules to consider liquidity transparency realtime trading and relatively low management fees are the reason why etfs are becoming more and more popular learn about the four key characteristics that investors should better understand in order to trade them properly more articles like this biotechnology value fund lp private company information  bloomberg july    am et capital markets company overview of biotechnology value fund lp snapshot people company overview biotechnology value fund lp is a hedge fund launched and managed bvf partners lp it invests in biotechnology sector biotechnology value fund lp was formed in  and is domiciled in the united states one sansome streetth floorsan francisco ca united statesfounded in  phone  fax  wwwbvflpcom key executives for biotechnology value fund lp mr mark n lampert founder manager and president age  mr matthew d perry portfolio manager age  compensation as of fiscal year  similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target private placement november   fate therapeutics inc mergeracquisition september   tobira therapeutics inc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact biotechnology value fund lp please visit wwwbvflpcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close biotechnology value fund ii lp  san francisco  ca  company information products resources my account talk to a db advisor  business directory ca san francisco investment offices nec management investment funds closedend biotechnology value fund ii lp b biotechnology value fund ii lp claim this business  sansome st ste  san francisco ca  get directions   wwwgcmlpcom business info founded  incorporated annual revenue  employee count  industries management investment funds closedend contacts mark lampert contact business your email address subject message send message company summary biotechnology value fund ii lp was founded in  biotechnology value fund ii lp specializes in management investment funds closedend verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   b view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved biotechnology value fund ii lp private company information  bloomberg july    am et capital markets company overview of biotechnology value fund ii lp snapshot people company overview biotechnology value fund ii lp is a hedge fund launched and managed bvf partners lp the fund is domiciled in the united states one sansome streetth floorsan francisco ca united statesfounded in  phone  fax  key executives for biotechnology value fund ii lp mr mark n lampert founder and president age  compensation as of fiscal year  similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target private placement november   fate therapeutics inc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact biotechnology value fund ii lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close   forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied   forbidden access is denied server error   forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied biotechnology value fund ii lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors biotechnology value fund ii lp check out list of companies and businesses related to biotechnology value fund ii lp find out biotechnology value fund ii lp address and contact details view other people related to biotechnology value fund ii lp  coworkers colleagues companions etc address  n michigan ave suite  chicago  il companies related to biotechnology value fund ii lp cikcompany namepositioncompany addresskent international holdings inc tillman hill road colleyville repligen corp seyon street building  suite  waltham ligand pharmaceuticals inc sorrento valley blvd suite  san diego capstone therapeutics corp west washington street suite  tempe icagen inc emperor blvd suite  durham neurocrine biosciences inc el camino real san diego neurobiological technologies inc ca crow canyon place suite  san ramon astex pharmaceuticals inc dublin blvd ste  dublin avigen inc de harbor bay parkway alameda arqule incone wall street burlington dynavax technologies corp seventh street suite  berkeley rigel pharmaceuticals inc veterans boulevard south san francisco adolor corp pennsylvania drive exton array biopharma inc walnut street boulder curis inc maguire road lexington catalyst biosciences inc littlefield avenue south san francisco epirus biopharmaceuticals inc boylston st th floor boston chemocentryx inc maude avenue mountain view celera corp harbor bay parkway alameda abbott biotherapeutics corp seaport blvd redwood city  biotechnology value fund ii lp on the web persons related to biotechnology value fund ii lp  kent international holdings incnamepositioncityasset value fund limited partnershipasset value fund limited partnership owner bedminsterasset value fund limited partnership owner bedministerasset value fund limited partnership owner bedministerbiotechnology value fund l pchicagobvf incilchicagobvf investments llcchicagobvf partners l pil chicagobryan p healeychief financial officer bedminsterbryan p healeychief financial officer far hillspaul o koetherchairman far hillspaul o koetherdirector far hillspaul o koetherchairman bedminsterpaul o koetherchairman far hillspaul o koetherchairman far hillspaul o koetherchairman far hillspaul o koetherchairman colleyvillepaul o koetherchairman colleyvillemark n lampertchicagorocco mastrodomenicomorris plainsrocco mastrodomenicodirector morris plainsqun yi zhengwaynequn yi zhengpresident bedminsterpersons related to biotechnology value fund ii lp  repligen corpnamepositioncitygoldberg alfredwalthamhunt anthonywalthamnicholas barthelemydirector carlsbadnicolas barthelemydirector walthamhoward benjaminvp business development lexingtonhoward benjamin walthamhoward benjaminvp business development walthambiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner chicagobvf partners l pilchicagoglenn l md cooperdirector lexingtonglenn l md cooperdirector walthamglenn l md cooperdirector walthamglenn l md cooperdirector walthamjohn coxdirector westonjohn coxdirector walthamwitt danielwalthamkaren a dawesdirector fremontkaren a dawesdirector walthamkaren a dawesdirector walthamkaren a dawesdirector walthamkaren a dawesdirector walthambarbara burnim dayvice president walthamcooper glennwalthamalfred lewis goldbergdirector walthamalfred lewis goldbergdirector walthammichael a griffithwalthammichael hallwalthamtimothy scott harris walthamrobert j hennesseydirector walthamrobert j hennesseydirector walthamearl webb henrydirector walthamearl webb henrywalthamearl webb henrydirector walthamwalter c herlihypresident ceo walthamwalter c herlihypresident ceo walthamwalter c herlihypresident ceo walthambenjamin howardwalthamanthony huntchief executive officer walthamrusche jameswalthamcox johnwalthamdawes karenwalthamwilliam j kellywalthamwilliam j kellyvice president walthamwilliam j kellycfo walthamwilliam j kellychief accounting officer walthammark n lampertsan franciscomark n lampertchicagohal landyvice president walthamjonathan i liebercfo walthamgriffith michaelwalthamg william millerdirector walthamdaniel w muehlcfo walthamglenn p muirdirector barthelemy nicolaswalthamalexander richdirector walthamalexander richdirector walthamjames r ruschesenior vice president walthamjames r ruschesenior vice president walthamjames r ruschesenior vice president walthamjames r ruschesenior vice president walthamthomas f ryan jrdirector walthamthomas f ryan jrdirector walthamthomas f ryan jrdirector walthampaul schimmeldirector walthamjon snodgrescfo walthamrobert spurrwalthamryan  jr thomaswalthamherlihy walterwalthamlaura whitehousevice president walthamdaniel p wittvice president walthamdaniel p wittvice president walthamdaniel p wittsr vp global operations walthamdaniel p wittsenior vice president walthampersons related to biotechnology value fund ii lp  ligand pharmaceuticals incnamepositioncitygiambattista aliprandisrvp tech sup  intl oper san diegojason aryehdirector san diegojason aryehdirector la jollajason aryehdirector la jollacharles s berkmanvp gen counsel  secretary san diegocharles s berkmanvp gen counsel  secretary la jollacharles s berkmanvp gen counsel  secretary la jollabiotechnology value fund l pchicagobiotechnology value fund l pchicagohenry f blissenbachhenry f blissenbachdirector mendota heightshenry f blissenbachdirector san diegohenry f blissenbachdirector san diegowarner r broaddusvp gen counsel  secy san diegowarner r broaddusvp gen counsel  secy san diegosteven j burakoffdirector new yorkbvf incilchicagobvf incilsan franciscobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pil owner chicagobvf partners l pil owner chicagobvf partners l pil owner chicagoberkman charlesla jollaalexander d crossalexander d crossdirector san diegoalexander d crossdirector san diegoalexander d crossdirector san diegotaylor crouchsr vp ops  pres intl san diegoknott davidla jollatodd c davisdirector san diegotodd c davisdirector la jollatodd c davisdirector la jollaterry a dembitzsan diegonishan m desilvavp finance  strategy and cfo westminsternishan m desilvavp corporate development la jollanishan m desilvavp corporate development la jollazofia e dziewanowskavp clinical research san diegomatthew w foehrpresident and coo palo altomatthew w foehrevp and coo la jollamatthew w foehrevp and coo la jollamatthew w foehrevp and coo la jollaelizabeth m greethamdirector san diegojohn groomdirector john groomdirector san diegojohn groomdirector san diegoeric s grovesvp project management san diegoeric s grovesvp project management san diegomelanie j hermandirector of accounting la jollajohn l higginschief executive officer palo altojohn l higginspresident  ceo la jollajohn l higginspresident  ceo la jollajohn l higginspresident  ceo san diegojohn l higginspresident  ceo la jollainvestment  llcchicagoinvestment  llcchicagoaryeh jasonla jollakozarich johnla jollahiggins johnla jollalamattina johnla jollairving s johnsonirving s johnsondirector san diegoirving s johnsondirector san diegoirving s johnsonsan diegoirving s johnsondirector san diegosyed kazmivp bus dev  strategic plan san diegosyed kazmivp bus dev  strategic plan la jolladavid m knottdirector syossetdavid m knottdirector syossetdavid m knottsyossetmatthew e korenbergvp finance and cfo la jollajohn w kozarichdirector san diegojohn w kozarichdirector san diegojohn w kozarichdirector san diegojohn w kozarichdirector la jollajohn w kozarichdirector la jollajohn l lamattinadirector new yorkjohn l lamattinadirector la jollajohn l lamattinadirector la jollamark n lampertsan franciscomark n lampertsan franciscomark n lampertchicagomark n lampertsan franciscoligand pharmaceuticals inc owner syossettjames j litaliensr vp reg affairs  comp san diegojames j litaliensr vp reg affairs  comp san diegodaniel s loebdirector new yorkdaniel s loebdirector new yorkpaul v maiersr vp cfo san diegopaul v maiersr vp cfo san diegopaul v maiersr vp cfo san diegokorenberg matthewla jollafoehr matthewla jollamartin meglassonmartin meglassonvp discovery research san diegomartin meglassonvp discovery research san diegomartin meglassonvp discovery research la jollaherman melaniela jollatod mertesvp controller  treasurer tod mertesvp controller  treasurer san diegoandres negrovilarexe vp r  d cso san diegoandres negrovilarexe vp r  d cso san diegosunil pateldirector mountain viewsunil pateldirector la jollasunil pateldirector la jollabruce peacockdirector berwyncarl c peckcarl c peckdirector san diegocarl c peckdirector san diegocarl c peckdirector san diegojeffrey r perrydirector new yorkwilliam a petttitsr vp hr and administration san diegowilliam a petttitsr vp hr and administration san diegobrigette robertsdirector new yorkdavid e robinsonpres ceo  chairman san diegodavid e robinsonpres ceo  chairman san diegodavid e robinsonpres ceo  chairman san diegomichael a roccamichael a roccadirector st louismichael a roccadirector san diegomichael a roccadirector san diegostephen l sabbadirector syossetjohn p sharpvp finance and cfo san diegojohn p sharpvp finance and cfo la jollajohn p sharpvp finance and cfo la jollasabba stephenla jollapatel sunilla jolladavis toddla jollapersons related to biotechnology value fund ii lp  capstone therapeutics corpnamepositioncitystuart h altmandirector tempebiotechnology value fund l pbiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilbvf incilchicagobvf incilchicagobvf investments llcbvf investments llcchicagobvf investments llc chicagobvf partners l pil bvf partners l pil owner chicagobvf partners l pilchicagomichael d caseydirector tempeeric w fangmanndirector tempeeric w fangmanndirector tempefredric j feldmandirector fredric j feldmandirector tempefredric j feldmandirector tempefredric j feldmandirector tempefredric j feldmandirector tempefredric j feldmandirector tempejohn m holliman iiiexecutive chairman tempejohn m holliman iiiexecutive chairman tempejohn m holliman iiiexecutive chairman tempejohn m holliman iiiexecutive chairman tempejohn m holliman iiiexecutive chairman tempejohn m holliman iiiexecutive chairman tempeelwood d howsedirector mercer islandelwood d howsedirector tempeelwood d howsedirector tempeelwood d howsedirector tempeelwood d howsedirector tempeholliman john iiitempemark n lampertsan franciscomark n lampertchicagotaeger lestempetaeger leslietempelloyd i miller iii owner napleslloyd i miller iii owner west palm beachjames m puseychief executive officer tempejames t phd ryabysr vp chief scientific officer tempedana b shinbaumsr vp business dev tempedana b shinbaumsr vp business dev tempedana b shinbaumvp business development temperobert j spiegeldirector temperobert j spiegeldirector temperandolph c steer birminghamrandolph c steerpresident temperandolph c steer temperandolph c steerpresident temperandolph c steerpresident templerandolph c steerpresident templerandolph c steerpresident temperandolph c steerpresident tempesherry a sturmanchief financial officer and vp tempeleslie m taegersvp chief financial officer leslie m taegerchief financial officer tempeleslie m taegerchief financial officer tempeleslie m taegersvp chief financial officer tempeleslie m taegersvp chief financial officer tempethomas r trotterchief executive officer tempewilliam m wardelldirector tempewilliam m wardelldirector tempewilliam m wardelldirector tempeaugustus a whitedirector tempeaugustus a whitedirector tempeaugustus a whitedirector tempepersons related to biotechnology value fund ii lp  icagen incnamepositioncitylaboratories abbott owner abbott parksrinivas akkarajumenlo parkalimentaria international inc owner lausannealta biopharma management llcsan franciscoalta biopharma partners lp owner san franciscoalta chase biopharma management llcsan franciscoalta embarcadero biopharma partners llcsan franciscopartners alta owner san franciscosteven r becker owner dallasbiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilchicagobvf investments llcchicagobvf partners l pil owner chicagobvf partners l pilchicagoholding capepariscdib bioventures inc owner taipeiphilippe o chambonnew yorkjacques chatainparischina development industrial bank inc owner taipeiagricole s a credit owner parisjeani delagardellemenlo parkjean deleagesan franciscoeclipse acquisition corpnew yorkmedical ventures european owner parisanthony b evnindirector new yorkanthony b evnindirector new yorkfinove ltd owner st helierde solidarite des travailleurs du quebec fonds owner montrealdennis b ph d gillingsdirector durhamdennis b ph d gillingsdirector durhamdennis b ph d gillingsdirector durhamdennis b ph d gillingsdirector durhamdennis b ph d gillingsdirector durhamdouglas e giordanonew yorkedward p graysr vp ip ch pat counsel sec durhamgarrett gruenersan franciscogutrafin ltd owner veltheimhbm bioventures cayman ltd owner grand caymanseth v hetheringtonsr vp clin  reg affairs durhamseth v hetheringtonsr vp clin  reg affairs durhaminvest as hoegh owner osloheyward hullsr vp dev and reg affairs durhamronald huntnew yorkicagen chase partners alta bio llcsan franciscoj p morgan partners sbic llc owner new yorkrobert james jakobssr dir finance  asst sec durhamdaniel janneysan franciscojp morgan partners bhca lpnew yorkjpmp capital corpnew yorkjpmp master fund manager l pnew yorkrichard d katzex vp fin  corp cfo  treas durhamandre lamottedirector durhamandre lamottedirector durhammark n lampertchicagovijay k lathimenlo parkh jefferson leightondirector durhamlilly eli  co owner indianapolisalix marduelsan franciscoruth mckernannew yorkmedical science ii coinvestment lpwalthammedical science partners ii l pwalthammedical science partners l p owner walthammerlin biomed private equity advisors llcnew yorkprivate foundation milton owner zugrichard g morrisondirector wilmingtonrichard g morrisondurhamneomed investments ltd owner hamiltonnew leaf venture associates ii lpnew yorknew leaf venture management ii llcnew yorknew leaf ventures ii lpnew yorkjames niedelnew yorkguy p nohrasan franciscoadeoye y olukotundirector durhamadeoye y olukotundirector durhampfizer inc owner new yorkpharma services holding incpharma services holding incdurhampharma services intermediate holding corppharma services intermediate holding corpdurhamqfinance incdurhamqfinance inc owner durhamquintiles transnational corpdurhamquintiles transnational corpdurhamwilliam g rochenew yorkround enterprises ltd owner st peter portcharles a sandersdirector durhamselectra investment  management ii inc owner londondominique semonnew yorkmartin a simonettidirector durhammartin a simonettidirector durhamg stacy smithdallasg stacy smithdallasg stacy smithdallassrb management lpdallasbryan suprannew yorkassociates venrock owner new yorkvenrock associates ii lp owner new yorkviking medical ventures ltd owner st helierkay wagonerpresident and ceo durhamkay wagonerpresident and ceo durhamkay wagonerpresident and ceo durhampatrick p walker owner dallaspatrick p walkerdallasreid s walkerdallasreid s walker dallaswalker smith capital l pdallaswalker smith capital qp l pdallaswalker smith international fund ltddallasws capital llcdallasws capital llcdallasws capital llcdallasws capital management lpdallasws capital management lpdallasws opportunity fund international ltddallasws opportunity fund l pdallasws opportunity fund qp l pdallasws ventures management l pdallasws ventures management l pdallasws ventures management l pdallasmanagement l l c wsvdallasmanagement l l c wsvdallasmanagement l l c wsvdallasyasuda enterprise development co ltdtokyoyasuda enterprise development ii lp owner tokyopersons related to biotechnology value fund ii lp  neurocrine biosciences incnamepositioncityadrian adamsdirector westoneric benevichchief commercial officer san diegobiotechnology value fund l pchicagobiotechnology value fund l pchicagohaig p bozigianchief development officer san diegohaig p bozigianchief development officer san diegohaig p bozigianchief development officer san diegobvf incilchicagobvf incilchicagobvf incilsan franciscobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pil owner chicagobvf partners l pilchicagobvf partners l pilchicagotimothy p coughlinchief financial officer san diegotimothy p coughlinchief financial officer san diegotimothy p coughlinchief financial officer san diegokyle ganochief business development off san diegokyle ganochief business dev officer san diegokevin charles gormanchief executive officer san diegokevin charles gormansr vp business development san diegokevin charles gormanpresident and ceo san diegokevin charles gormanpresident and ceo san diegokevin charles gormanpresident  ceo san diegokevin charles gormanpresident and ceo san diegodimitri e grigoriadischief research officer san diegodimitri e grigoriadischief research officer san diegodimitri e grigoriadischief research officer san diegodavidalexandre c grospresident  coo cambridgepaul w hawranexecutive vp and cfo san diegopaul w hawranexecutive vp and cfo san diegopaul w hawranexecutive vp and cfo san diegoanders d hovenew yorkanders d hovenew yorkmark n lampertchicagomark n lampertchicagodarin lippoldtchief legal officer san diegodarin lippoldtchief legal officer san diegorobert j littlesvp commercial operations san diegomalcolm lloydsmithchief regulatory officer san diegomalcolm lloydsmithchief regulatory officer san diegomalcolm lloydsmithchief regulatory officer san diegocorinne h lyledirector irvinecorinne h lyledirector irvinegary a lyonsdirector palo altogary a lyonspresident and ceo san diegogary a lyonspresident and ceo san diegow thomas mitchelldirector la quintaw thomas mitchelldirector san diegojoseph a mollicadirector joseph a mollicadirector cranburyjoseph a mollicadirector princetonjoseph a mollicadirector cranburyjoseph a mollicadirector cranburygeorge j morrowdirector neurocrine biosciences incdirector san diegocorinne h nevinnydirector irvinecorinne h nevinnydirector san diegochristopher flint obrienchief medical officer san diegochristopher flint obriensr vp  chief medical officer san diegochristopher flint obrienchief medical officer san diegochristopher flint obrienchief medical officer san diegohenry panexecutive vp and cmo san diegohenry panexecutive vp and cmo san diegorichard f popsdirector cambridgerichard f popsdirector walthamrichard f popsdirector cambridgerichard j ranierisr vp human resources san diegorichard j ranierisr vp human resources san diegowilliam h rastetterdirector william h rastetterdirector san diegobryan e robertspalo altoalfred sandrockdirector westonstephen a sherwindirector south san franciscostephen a sherwindirector san diegostephen a sherwindirector south san franciscolawrence steinmandirector stanfordlawrence j steinmancynthia j thomassan diegowylie w valedirector la jollajensen margaret e valeursenior vp and general counsel san diegojensen margaret e valeursenior vp and general counsel san diegojensen margaret e valeurevp and general counsel san diegojensen margaret e valeurevp and general counsel san diegovenrock healthcare capital partners lppalo altovhcp coinvestment holdings llcpalo altovhcp management llcpalo altowendall wierengaevp research  development san diegowendall wierengaevp research  development san diegowendall d wierengasan diegowendall d wierengaevp research  development san diegopersons related to biotechnology value fund ii lp  neurobiological technologies inc canamepositioncitybiotechnology value fund l pchicagobiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilchicagobvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner chicagobvf partners l pilchicagoenoch callawaydirector richmondenoch callawaydirector richmondenoch callawaydirector emeryvilleronald caperichmondronald capedirector emeryvillecraig w carlsonemeryvillcraig w carlsonvp and chief financial officer emeryvillelisa u md phd carrsr vice president richmondlisa u md phd carrsr vice president emeryvilleabraham e cohendirector richmondabraham e cohendirector richmondabraham e cohendirector emeryvillejames d dondero owner dallastheodore eliotdirector richmondtheodore eliotdirector emeryvilletheodore eliotdirector emeryvillefirefly management co gp llcnew yorkfirefly value partners lp owner new yorkwilliam a fletcheracting chief executive officer emeryvillepaul e freiman san franciscopaul e freimanpresident and ceo richmondpaul e freimanpresident and ceo emeryvillefvp gp llcnew yorkfvp master fund lpnew yorkfvp usq lpnew yorkryan heslopnew yorkhighland capital management lp owner dallasj p morgan chase  co owner new yorkf van kasperdirector richmondf van kasperdirector richmondf van kasperdirector emeryvillemichael a kaufmannew yorkmark n lampertchicagodavid e levyrichmonddavid e levyvp of clinical development emeryvillematthew m loarvp and chief financial officer emeryvillemak capital fund lpnew yorkmak capital one llcnew yorkstephen j pettirichmondstephen j pettivp of product development emeryvillemichael rothst francisabraham d sofaerdirector richmondabraham d sofaerdirector richmondabraham d sofaerdirector emeryvillebrian jay starkst francisstrand advisors incdallasjohn b stuppindirector richmondjohn b stuppindirector emeryvilles donald sussmanst thomasariel warszawskinew yorkwarren w wasiewskivice president cmo emeryvillejonathan r wolterrichmondjonathan r woltervp and chief financial officer emeryvillepersons related to biotechnology value fund ii lp  astex pharmaceuticals incnamepositioncitygoldberg allanteaneckmohammad azabchief medical officer dublinmohammad azabchief medical officer dublindavid bearsschief scientific officer dublingregory berkchief medical officer dublinbiotechnology value fund l pchicagobiotechnology value fund l pchicagomartin bucklandchief business officer cambridgemartin bucklandchief business officer cambridgebvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner chicagobvf partners l pilchicagocharles j casamentodirector dublincharles j casamentodirector union citycharles j casamentodirector san franciscocharles j casamentodirector san franciscocharles j casamentodirector dublincasamento charleskenwoodpeter fellnerdirector winnersh berkshirepeter fellnerdirector winnersh berkshirethomas v girardidirector los angelesallan r goldbergdirector new yorkallan r goldbergdirector teanecktimothy hainesdirector londonchristian hansencopenhagen kedward l jacobschief operating officer dublinaudrey f jakubowskichief reg  quality officer dublinmanuso jamesdublinharren jhotipresident cambridgeharren jhotipresident cambridgeismail koladirector cambridgeismail koladirector cambridgewalter j lackdirector los angelesmark n lampertchicagojames s j manusochief executive officer dublinjames s j manusochief executive officer dublinkarl l mettingersr vp chief medical officer dublinyoung michaeldevonmolkentin michaeldublinazab mohammaddublinmichael molkentinchief financial officer dublinmichael molkentinchief financial officer dublinpublic equity ks nb owner copenhagen kjoseph rubinfelddirector dublinflorian schonhartingcopenhagen kgirardi thomaslos angeleslack walterlos angelesmichael d youngdirector devonpersons related to biotechnology value fund ii lp  avigen inc denamepositioncitybiotechnology value fund l pchicagobiotechnology value fund l pchicagoburlingame asset management llc owner san franciscoburlingame asset management llc owner san franciscobvf acquisition llcchicagobvf incilchicagobvf incilsan franciscobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pil owner chicagobvf partners l pilchicagokenneth chahinechief executive officer alamedakenneth chahinechief executive officer alamedakenneth chahinechief executive officer alamedakenneth chahinechief executive officer alamedakenneth chahinedirector alamedamichael denis coffeechief business officer alamedamichael denis coffeechief business officer alamedarobert m coppedgeseattlestephen george dillydirector alamedahoward goldengreenwichhoward goldengreenwichzola p horovitzdirector alamedazola p horovitzdirector plymouth meetingzola p horovitzdirector alamedazola p horovitzdirector alamedazola p horovitzdirector alamedayuichi iwakidirector yuichi iwakidirector alamedayuichi iwakidirector alamedayuichi iwakidirector alamedayuichi iwakidirector alamedayuichi iwakidirector alamedakirk william johnsonvp research and development alamedakirk william johnsonvp preclinical development alamedamark n lampertsan franciscomark n lampertchicagodawn mcguirechief medical officer alamedadawn mcguirechief medical officer alamedaoleg nodelmansan franciscojan k ohrstromdirector alamedajan k ohrstromdirector alamedathomas j paulsonthomas j paulsonchief finance officer  secty alamedathomas j paulsonchief finance officer  secty alamedathomas j paulsonalamedamatthew d perrysan franciscoglenn piercevp research  clinical dvlpt alamedajohn k a prendergastdirector alamedajohn k a prendergastdirector alamedaandrew august sauterceo president and cfo alamedasouthpaw asset management lp owner greenwichsouthpaw credit opportunity master fund lp owner greenwichsouthpaw holdings llcgreenwichmary christina thomsonvp corp counsel  secretary alamedamary christina thomsonvp corporate counsel alamedadaniel vapnekdirector alamedadaniel vapnekdirector alamedadaniel vapnekdirector alamedarichard john wallacedirector alamedarichard john wallacedirector alamedaphilip j whitcomechairman of the board of direc alamedaphilip j whitcomechairman of the board of direc alamedaphilip j whitcomechairman of the board of direc alamedakevin wymangreenwichkevin wymangreenwichpersons related to biotechnology value fund ii lp  arqule incnamepositioncitymichael j astruedirector cambridgemichael j astruedirector woburnlaura avakiandirector woburntimothy c barabedirector woburntimothy c barabedirector woburntimothy c barabedirector woburntimothy c barabedirector woburntimothy c barabedirector woburntimothy c barabedirector wobrunbiotechnology value fund l pchicagobiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilchicagobvf incilsan franciscobvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pil owner chicagobvf partners l pil owner chicagobvf partners l pilchicagowerner cautreelsdirector woburnthomas c k chanchief scientific officer woburnrichard a charpiewellesleyariel eliadirector woburnngoc tuan hadirector woburnstephen a hillpresident and ceo woburnj david jacobsvp and general counsel woburnsusan l kelleydirector woburnmark n lampertchicagomark n lampertchicagopeter s lawrencepresident  coo woburnchiang j lievp chief scientific officer woburnchiang j livp chief scientific officer norwoodronald m lindsaydirector san diegoronald m lindsaydirector woburnmichael d lobergdirector cambridgemichael d lobergdirector woburnmichael d lobergdirector woburnmichael d lobergdirector woburnmichael d lobergdirector woburnmichael d lobergdirector woburnlouise mawhinneyvp and chief financial officer woburnlouise mawhinneyvp finance treasurer and cfo woburnwilliam g messengerdirector woburnpfizer inc owner new yorkpaolo puccichief executive officer woburnnigel j rulewskiformer chief medical officer woburnbrian schwartzchief medical officer bostonbrian schwartzchief medical officer woburnbrian schwartzchief medical officer woburnnancy a simoniandirector woburnrobert j weiskopfchief financial officer bedfordrobert j weiskopfvice president of finance woburnrobert j weiskopfvice president of finance woburnrobert j weiskopfvice president of finance woburnrichard h woodrichwoburnpatrick j zennerdirector patrick j zennerdirector woburnpatrick j zennerdirector woburnpersons related to biotechnology value fund ii lp  dynavax technologies corpnamepositioncityalta california management partners lpsan franciscoalta california partners lpsan franciscoalta embarcadero partners llcsan franciscopartners altasan franciscooronsky phd arnoldberkeleybiotechnology value fund l pchicagobiotechnology value fund l pchicagolouis c bockdirector foster citylaura bregedirector emeryvillelaura bregedirector berkeleynancy l bucdirector washingtonnancy l bucdirector washingtonnancy l bucdirector washingtonnancy l bucdirector berkeleybvf incilsan franciscobvf incilchicagobvf incilsan franciscobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pil owner san franciscobvf partners l pil owner chicagobvf partners l pilchicagofrancis canodirector los altosfrancis canodirector berkeleydennis carsondirector la jolladennis carsondirector la jolladennis carsondirector la jolladennis carsondirector la jolladennis carsondirector la jolladennis carsondirector la jolladennis carsondirector berkeleyrobert coffmansenior vice president berkeleyrobert coffmanvp  chief scientific officer berkeleyrobert coffmanvp and chief scientific off berkeleyrobert coffmanvp  chief scientific officer berkeleyrobert coffmanchief scientific officer  vp berkeleyrobert coffmanchief scientific officer  vp berkeleyrobert coffmanvp  chief scientific officer berkeleyrobert coffmanchief scientific officer  svp berkeleylawrence md davidberkeleywilliam j dawsonberkeleywilliam j dawsonkentfielddeerfield capital lpnew yorkdeerfield international ltdroad town tortola ddeerfield international ltdroad town tortolamanagement co ny deerfieldnew yorkdeerfield partners lpnew yorkdeerfield private desigan fund l pnew yorkdeerfield private design international lpnew yorkdeerfield special situations fund international ltdroad town tortoladeerfield special situations fund lpnew yorkjean deleagesan franciscogilbert phd deniseberkeleycarson md dennisberkeleydino dinaberkeleydino dinapresident and ceo berkeleydino dinapresident ceo and director berkeleydino dinadirector berkeleydina md dinoberkeleyjames e flynn owner new yorkcano phd francisberkeleydenise gilbertdirector portola valleydenise gilbertdirector portola valleydenise gilbertdirector berkeleyeddie grayceo and director berkeleyeddie grayceo and director berkeleygarrett gruenersan franciscotimothy g hennberkeleytimothy g hennvice president berkeleytimothy g hennvp finance  administration berkeleydaniel janneydirector san franciscodaniel janneydirector san franciscodaniel janney san franciscozbigniew janowiczdirector dusseldorfzbigniew janowiczceo dynavax europe berkeleyrobert janssenvice president berkeleylew jenniferberkeleydavid louis johnsonvice president haywarddavid louis johnsonvice president  cao berkeleymark kesseldirector berkeleymark kesseldirector berkleydaniel l kisnerdirector san diegodaniel l kisnerdirector berkeleymark n lampertchicagochristine r larsonvp and chief financial officer berkeleydavid m lawrencedirector berkeleydavid m lawrencedirector berkeleyjan leschlydirector new yorkjan leschlyprincetonjan leschlydirector princetonjan leschlydirector princetonjan leschlydirector princetondaniel j levittberkeleydaniel j levittvice president berkeleyjennifer lewvp finance  pao berkeleykessel markberkeleyj tyler martinpresident cmo  director berkeleyostrach michaelberkeleybuc nancyberkeleyguy p nohrasan franciscodavid f novacksenior vice president berkeleydavid f novacksenior vice president berkeleyarnold l oronskydirector menlo parkarnold l oronskydirector berkeleyarnold l oronskydirector menlo parkarnold l oronskydirector menlo parkmichael s ostrachsenior vice president michael s ostrachchief business officer berkeleymichael s ostrachvice president berkeleyphilips peggyberkeleypeggy v phillipsdirector berkeleypeggy v phillipsdirector berkeleystanley a plotkindirector doylestownstanley a plotkindirector berkeleynatale s riccardidirector augustanatale s ricciardidirector berkeleynatale s ricciardidirector berkeleycoffman phd robertberkeleymartin e sandersevp chief development officer berkeleymartin e sandersevp and cdo berkeleydeborah a smeltzervp operations  cfo berkeleydeborah a smeltzervice president and cfo berkeleydeborah a smeltzervp operations and cfo berkeleydeborah a smeltzervp operations  cfo berkeleyplotkin md stanleyberkeleysymphony capital gp lpnew yorksymphony capital partners lpdirector new yorksymphony gp llcnew yorksymphony strategic partners llcnew yorkharri v tarantonew yorkstephen f tuckberkeleystephen f tuckvice president berkeleystephen f tuckvp biopharmaceutical developmt berkeleystephen f tuckvp global technical ops berkeleynest gary a vanberkeleynest gary a vanvice president berkeleynest gary a vanvp preclinical research berkeleyjanowicz phd zbigniewberkeleypersons related to biotechnology value fund ii lp  rigel pharmaceuticals incnamepositioncityalta biopharma management ii llcsan franciscoalta biopharma partners ii lpsan franciscoalta california management partners lpsan franciscoalta california partners lpsan franciscoalta embarcadero biopharma partners ii llcsan franciscoalta embarcadero partners llcsan franciscopartners altasan franciscoalta partners ii inc owner san franciscobiotechnology value fund l pchicagobiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilchicagobvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner chicagobvf partners l pil owner chicagobvf partners l pilchicagofarah champsisan franciscorobin d g coopersr vp pharmaceutical scs south san franciscorobin d g coopersr vp pharmaceutical scs south san franciscodeerfield capital lpnew yorkdeerfield international ltdtortolamanagement co ny deerfieldnew yorkdeerfield partners lpnew yorkdeerfield special situations fund international ltdroad town tortoladeerfield special situations fund lpnew yorkjean deleagedirector south san franciscojean deleagedirector san franciscojean deleagedirector san franciscoannemarie duliegechief medical officer palo altokurt von emsterbostonluke evnin owner bostonluke evninbostonfhm iv llcseattlefhm iv lpseattlejames e flynn owner new yorkalan d frazierdirector seattlealan d frazierdirector seattlealan d frazierdirector seattlealan d frazierdirector seattlealan d frazierdirector seattlefrazier healthcare iv lp owner seattleansbert gadicke owner bostonansbert gadickebostonnicholas galakatos owner bostonnicholas galakatosbostonbradford s goodwindirector south san franciscobradford s goodwindirector south san franciscobradford s goodwindirector south san franciscojames m gowerceo  board chairman south san franciscojames m gowerceo  board chairman south san franciscoelliot b grossbardevp cmo south san franciscoelliot b grossbardsr vp medical development south san franciscoelliott b grossbardevp cmo south san franciscogarrett gruenersan franciscodennis hennerdirector bostoninvestment  llcchicagokeith katkindirector san diegomark n lampertsan franciscomark n lampertsan franciscomark n lampertchicagojoseph lasagavp bus dev alliance mgmt south san franciscorobert liptakbostongary a lyonsdirector palo altogary a lyonsdirector south san franciscogary a lyonsdirector south san franciscoalix marduelsan franciscoesteban masudasr vp research south san franciscoeldon c mayer iiievp  chief commercial officer south san franciscoryan d maynardevp  cfo south san franciscoryan d maynardevp  cfo south san franciscowalter h moosdirector san diegowalter h moosdirector oaklandwalter h moosdirector menlo parkwalter h moosdirector south san franciscompm asset management investors  bviii llcbostonmpm bioequities fund gmbh  co kgbostonmpm bioequities gp llcbostonmpm bioequities gp lpbostonmpm bioequities master fund lp owner bostonmpm bioventures iii gmbh  cobostonmpm bioventures iii gp lpbostonmpm bioventures iii llcbostonmpm bioventures iii lpbostonmpm bioventures iii parallel fundbostonmpm bioventures iii qp lp owner bostonguy p nohrasan franciscodonald g payanevp pres discoveryresearch south san franciscodonald g payanevp pres discoveryresearch south san franciscodonald g payanevp pres discoveryresearch south san franciscohollings rentondirector south san franciscohollings rentondirector richmondhollings rentondirector emeryvillehollings rentondirector south san franciscopeter s ringrosedirector south san franciscopeter s ringrosedirector south san franciscoraul r rodriguezceo president south san franciscoraul r rodriguezceo president south san franciscostephen a sherwindirector south san franciscostephen a sherwindirector south san franciscostephen a sherwindirector foster citystephen a sherwindirector south san franciscostephen a sherwindirector south san francisconicholas j simon iiidirector bostonnicholas j simon iiidirector bostonnicholas j simon iiidirector san franciscomichael steinmetz owner bostonmichael steinmetzbostondolly vanceevp corp affairs gc sect south san franciscodolly vanceevp corp affairs gc sect south san franciscojames h welchcfo vp  secretary south san franciscojames h welchcfo vp  secretary south san franciscokurt wheelerbostonpersons related to biotechnology value fund ii lp  adolor corpnamepositioncity capital gp llc owner new york capital gp llc owner new yorkarmando anidodirector gaithersburgarmando anidodirector extonarmando anidodirector extonarmando anidodirector extonbaker biotech capital gp llc owner new yorkbaker biotech capital gp llc owner new yorkbaker bros capital gp llc owner new yorkbaker bros capital gp llc owner new yorkbaker brothers life sciences capital gp llc owner new yorkbaker brothers life sciences capital gp llc owner new yorkfelix bakernew yorkfelix bakernew yorkjulian bakernew yorkjulian bakernew yorkbaker  tisch capital gp llc owner new yorkbaker  tisch capital gp llc owner new yorkjames e barrettsr vpcso  presidentresearch biotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilsan franciscobvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pil owner chicagobvf partners l pilchicagocubist pharmaceuticals inclexingtoncubist pharmaceuticals inc owner lexingtoncubist pharmaceuticals inc owner lexingtonmichael r doughertypresident  ceo extonmichael r doughertysenior vp coo  cfo extonmichael r doughertysvp  chief operating officer extonellen feeneyfrd acquisition corplexingtonfrd acquisition corplexingtonfrd acquisition corplexingtongeorges gemayelextongeorges gemayeldirector georges gemayeldirector extonpaul goddarddirector extonpaul goddarddirector extonroger d graham jrsvp sales  marketing extongeorge v hager jrgeorge v hager jrdirector kennett squaregeorge v hager jrdirector kennett squaregeorge v hager jrdirector extongeorge v hager jrdirector extonthomas p hessvp finance  cfo extondavid jacksonsr vp and cmo extonmark n lampertsan franciscomark n lampertchicagomark n lampertsan franciscojohn m limongellisvp general counsel  secr extondavid maddendavid maddendirector extondavid maddendirector extondavid maddendirector extondavid maddendirector extonguido magnidirector extonmartha e manningsrvp general counsel  sec extongeorge r maurersvp mfg  pharm technologies extonclaude nashdirector extonclaude nashdirector extonclaude nashdirector extonclaude nashdirector extonclaude nashdirector extonrobert nelsendirector chicagorobert nelsendirector chicagodonald e nickelsondirector donald e nickelsondirector extondonald e nickelsondirector extondonald e nickelsondirector extonbruce peacockpresident and ceo bruce peacockpresident and ceo extoneliseo oreste salinassvp rd  cmo extonstephen w webstersvp finance  cfo extonpersons related to biotechnology value fund ii lp  array biopharma incnamepositioncitycharles m baumdirector san diegocharles m baumdirector boulderbiotechnology value fund l pchicagobiotechnology value fund l pchicagofrancis j bullockdirector lincolnfrancis j bullockdirector boulderbvf incilchicagobvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner chicagobvf partners l pilchicagobvf partners l pil chicagomichael carrutherscfo bouldermichael carrutherschief financial officer bouldermichael carrutherscfo bouldermichael carrutherscfo bouldermarvin h caruthersdirector bouldermarvin h caruthersdirector boulderrobert conwayceo boulderrobert conwayceo bouldersnitnam davidboulderwilliams douglasboulderbullock francisbouldergwen a fyfe sunnyvalegwen a fyfedirector bouldervan lunsen gilboulderjeremy greensan franciscojason haddockcfo bouldermary p henahanboulderdavid j horinnewport beachzabriskie johnbouldermoore johnboulderkoch kevinboulderkevin kochpresident cso boulderkevin kochpresident  cso boulderlefkoff kylebouldermark n lampertchicagomark n lampertchicagomark n lampertsan franciscokyle lefkoffdirector boulderkyle lefkoffboulderkyle lefkoffdirector boulderkyle lefkoffdirector boulderkyle lefkoffdirector bouldercaruthers marvinboulderjohn r moorevp general counsel boulderjohn r moorevp general counsel boulderjohn r moorevp general counsel bouldermichael n needlecmo bouldermichael n needlecmo boulderjohn a orwin san mateojohn a orwindirector san mateojohn a orwindirector redwood citytony piscopiovice president chemistry bouldercarruthers rboulderliam ratcliffedirector new yorkliam ratcliffedirector new yorkredmile group llc owner san franciscoandrews r robbinscoo boulderandrews r robbinssvp commercial operations boulderconway robertbouldernicholas a saccomanocso bouldernicholas a saccomanocso bouldervictor sandorchief medical officer bouldershalini sharpnew yorkdavid snitmancoo and vp business devel boulderdavid snitmancoo and vp bus development boulderdavid snitmancoo and vp business devel boulderron squarerceo lake forestron squarerboulderron squarerceo boulderron squarerceo boulderlunsen gil j vandirector durangolunsen gil j vandirector boulderlunsen gil j vandirector boulderlunsen gil j vandirector boulderlunsen gil j vandirector boulderdouglas e williamsdirector bothelldouglas e williamsdirector boulderjohn yatescmo boulderjohn l zabriskiedirector boulderjohn l zabriskiedirector bostonpersons related to biotechnology value fund ii lp  curis incnamepositioncityrichard aldrichbostonrichard aldrichbostonaurigene discovery technologies ltd owner bangalore karnatakasusan b bayhsusan b bayhdirector cambridgesusan b bayhdirector lexingtonsusan b bayhdirector indianapolissusan b bayhdirector cambridgesusan b bayhdirector cambdridgebiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilsan franciscobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pilchicagostephen carterdirector cambridgepasseri daniellexingtonjoseph m daviedirector joseph m daviedirector cambridgejoseph m daviedirector cambridgejoseph md phd daviedirector cambridgejoseph md phd daviedirector lexingtonjames e dentzerchief financial officer cranburydr reddys holdings ltdhyderabad telanganadr reddys laboratories ltdhyderabad telanganaali phd fattaeypresident  ceo lexingtonmichael graycfo cambridgemichael graychief financial officer cambridgemichael graycoo and cfo cambridgemichael graycfo lexingtonmartyn d greenacredirector martyn d greenacredirector cambridgemartyn d greenacredirector lexingtonmartyn d greenacredirector west chestermartyn d greenacredirector cambridgemcnab jr jameslexingtontobin jameslexingtonkenneth i kaitindirector cambrdigekenneth i kaitindirector cambridgekenneth i kaitindirector bostonkenneth i kaitindirector cambridgekenneth i kaitindirector cambridgekenneth i kaitindirector lexingtonmitchell keeganvicepresident cambridgemitchell keeganvicepresident lexingtonkaitin kennethlexingtonpeter kolchinskybostonpeter kolchinskybostonruth b kunathlori anne kunkeldirector sunnyvalerubin marclexingtonnoel marklexingtonrobert martelldirector lexingtongreenacre martynlexingtonvoi mauriziolexingtonjames r mcnabdirector james r mcnabdirector cambridgejames r mcnabdirector cambridgejames r mcnabdirector cambridgejames r mcnabdirector lexingtondouglas meltondouglas meltondirector cambridgedouglas meltondirector cambridgegray michaellexingtonchristopher u misslingchristopher u misslingsr vp strategic planning cambridgemani mohindruchief strategy officer lexingtonmark noelmark noelvice president tech manage cambridgemark noelvp tech management cambridgemark noelvicepresident cambridgemark noelvp tech management lexingtondaniel r passeridirector daniel r passeripresident and ceo cambridgedaniel r passericeo and director cambridgedaniel r passericeo and director cambridgedaniel r passeridirector lexingtonkenneth pientadirector lexingtonmary elizabeth potthoffmary elizabeth potthoffvice presidentgeneral counsel cambridgemary elizabeth potthoffvp and general counsel cambridgechanggeng qianvp research  preclinical dev cambridgechanggeng qianvp research  preclinical dev lexingtonra capital biotech fund ii lpbostonra capital biotech fund ii lpbostonra capital biotech fund lpbostonra capital biotech fund lpbostonra capital management llcbostonra capital management llc owner bostonmartell robertlexingtonlee l rubinlee l rubinvice president research cambridgelee l rubinvp of research cambridgemarc rubindirector englewoodmarc rubindirector cambridgemarc rubindirector lexingtonbayh susanlexingtonjames r tobinjames r tobindirector lexingtonjames r tobindirector cambridgejames r tobindirector cambridgejames r tobindirector cambridgedavid tuckchief medical officer lexingtonjaye vinerchief medical officer lexingtonmaurizio voichief medical officer lexingtonpersons related to biotechnology value fund ii lp  catalyst biosciences incnamepositioncitym james barrettdirector baltimorem james barrett owner timoniumpeter j barris owner baltimorepeter j barris owner timoniummerouane bencherifsvp preclinical research winstonsalemmerouane bencherifsvp and senior scien fellow winstonsalembiotechnology value fund l pbiotechnology value fund l pchicagobiotechnology value fund l pchicagobiotechnology value fund l pchicagocharles a blixtdirector winstonsalemcharles a blixtdirector winstonsalemcharles a blixtdirector winstonsalemjeffrey p brennansvp  bus  commercial dev winstonsalemjeffrey p brennansvp bus and comm dev  cbo winstonsalemjulia r browndirector san diegojulia r browndirector winstonsalemsteven burrillsan franciscosteven burrilldirector winstonsalembvf incilbvf incilchicagobvf incilchicagobvf incilchicagobvf investments llcbvf investments llcchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pilbvf partners l pil owner chicagobvf partners l pilchicagobvf partners l pilchicagowilliam s caldwellsvp  drug discovery and dev winstonsalemj donald debethizypresident and ceo winstonsalemerrol b desouzadirector errol b desouzadirector winstonsalemerrol b desouzadirector winstonsalemgeoffrey c dunbarsvp clin dev  reg affairs winstonsalemalan w duntondirector king of prussiaalan w duntondirector winstonsalemalan w duntondirector winstonsalemalan w duntondirector winstonsalemessex woodlands health ventures viii llcthe woodlandsessex woodlands health ventures viii lpthe woodlandseuclidsr associates lpnew yorkeuclidsr biotechnology associates lp owner new yorkeuclidsr biotechnology partners lpnew yorkeuclidsr partners lp owner new yorkann hanhamdirector winstonsalemkaren a hicksvp human resources winstonsalemkaren a hicksvp human resources winstonsalemstephen a hilldirector woburnstephen a hillpresident and ceo winstonsalemjeff himawandirector san diegomauri k hodgesvp fincorp sys and controller winstonsalemmauri k hodgesvp fincorp sys  controller winstonsalemmauri k hodgeswinstonsalemdavid a hosfordwinstonsalemdavid a hosfordvp clin dev  reg affairs winstonsalemdavid a hosfordvp clin dev  reg affairs winstonsaleminvestment  llcchicagoinvestment  llcchicagoelaine v jonesdirector new yorkelaine v jonesdirector winstonsalemc richard kramlich owner baltimorec richard kramlich owner timoniummark n lampertsan franciscomark n lampertchicagomark n lampertchicagomark n lampertchicagoaugustine lawlordirector cambridgehoward levychief medical officer south san franciscoedwin madisonchief scientific officer south san franciscopeter morris owner baltimoralan a mussosvp cfo  treasurer winstonsalemalan a mussosvp finadmin cfo  treas winstonsalemalan a mussosvp finadmin cfo  treas winstonsalemnea partners  l p owner baltimorenew enterprise associates  l p owner baltimorecharles w newhall iii owner baltimoreinternational plc nomuralondoninternational plc nomura owner united kingdominternational plc nomuraunited kingdomnomura phase ventures gp ltdlondonnomura phase ventures lplondonnomura phase ventures lplondonnomura phase ventures ltdlondonnomura phase ventures ltdlondonfletcher paynechief financial officer south san franciscomark w perry owner baltimorejohn p richarddirector cambridgejohn p richarddirector winstonsalemjohn p richarddirector winstonsalemjohn p richarddirector winstonsalempatrick c rocksvp gc and secretary winstonsalemscott d sandell owner baltimorescott d sandell owner timoniumharold e selickdirector redwood citymark b skaletskydirector winstonsalemmark b skaletskydirector winstonsalemmark b skaletskymember office of the chairman winstonsalemralph snydermandirector winstonsalemsteven m tolerwinstonsalemsteven m tolervp clin pharm sciences winstonsalemsteven m tolervp clin pharm sciences winstonsalemeugene a trainor iii owner baltimorenassim usmanpresident  ceo peter a zornvp lg affrs gc and secretary winstonsalempeter a zornsvp lgl affrs gc  secretary winstonsalempeter a zornsvp lgl affrs gc  secretary winstonsalempersons related to biotechnology value fund ii lp  epirus biopharmaceuticals incnamepositioncityam coinvestors iii lpmenlo parkam coinvestors iii lpmenlo parkam partners iii llcmenlo parkam partners iii llc owner menlo parkam ventures iii lpmenlo parkam ventures iii lpmenlo parkrichard aldrichbostonrichard aldrichdirector cambridgeangiotech pharmaceuticals incvancouverangiotech pharmaceuticals inc vancouverlynn g bairdsenior vp  regulatory affairs cambridgelynn g bairdsenior vp  regulatory affairs cambridgelynn g bairdsenior vp  reg affairs cambridgelynn g bairdsenior vp  regulatory affairs cambridgelynn g bairdsvp regulatory affairs cambridgejohn v balenrowaytonbiotechnology value fund l pchicagobiotechnology value fund l pchicagodavid bondermanfort worthdavid bondermanfort worthalexis borisypresident  ceo bostonalexis borisyceo  president cambridgealexis borisyceo  president cambridgealexis borisyceo  president cambridgej kevin buchidirector j kevin buchidirector bostonbvf incilchicagobvf incilsan franciscobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner san franciscobvf partners l pil owner chicagobvf partners l pilchicagocanaan equity ii entrepreneurs llcrowaytoncanaan equity ii entrepreneurs llcrowaytoncanaan equity ii lp qprowaytoncanaan equity ii lp qprowaytoncanaan equity ii lprowaytoncanaan equity ii lprowaytoncanaan equity partners ii llcrowaytoncanaan equity partners ii llc owner rowaytoncanaan equity partners ii llcrowaytoncharmers landing llcrowaytongallen christophercambridgedouglas coledirector bostonjason colesenior vp and general counsel bostonjason colesenior vp  general counsel cambridgejason colesenior vp  gencounsel cambridgejason colesenior vp  general counsel cambridgejason colesvp  general counsel cambridgejason colesenior vp  general counsel cambridgejason coleevpcorp dev  general counsel cambridgemark corrigandirector marlboroughmark corrigandirector bostonmark corriganpresident  ceo cambridgemark corrigandirector cambridgemark corriganpresident  ceo cambridgejames g coulterfort worthjames g coulterfort worthsally crawforddirector cambridgesally crawforddirector cambridgekamra deepakrowaytonmark j deninowaynebarbara deptuladirector bostonbarbara deptuladirector cambridgebarbara deptuladirector cambridgejohn d diekmanmenlo parkjohn d diekmanmenlo parkgeoffrey m duykdirector geoffrey m duykfort worthtodd foleycambridgetodd foleydirector cambridgetodd foleydirector cambridgerobert forresterexecutive vp  cfo bostonrobert forresterexecutive vp  cfo cambridgerobert forresterevp and cfo cambridgerobert forresterevp  cfo cambridgerobert forresterevp  cfo cambridgerobert forresterevp  cfo cambridgerobert forresterevp and coo cambridgepatrick j fortunedirector bostonpatrick j fortunedirector cambridgepatrick j fortunedirector cambridgehaydu frankcambridgedaotian fudirector gongbei zhuhai city guangdongjames c furnivallrowaytonansbert gadickebostonnicholas galakatosbostonchristopher c gallenevp research  development cambridgechristopher c gallenevp research  development cambridgechristopher c gallenevp research  development cambridgejacob goldfielddirector bostondaniel grausen vp commercial operations bostondaniel grauchief operating officer cambridgedaniel grauchief operating officer cambridgedaniel grauchief operating officer cambridgedaniel grauchief operating officer cambridgel stephen greenrowaytonrichardson hartleycambridgefrank haydudirector cambridgefrank haydudirector cambridgefrank haydubostonfrank haydudirector cambridgefrank haydudirector cambridgedennis hennerbostonwilliam l hunterdirector vancouverwilliam l hunterdirector cambridgewilliam l hunterdirector cambridgewilliam l hunterdirector cambridgewilliam l hunterdirector bostoncole jasoncambridgerenz justincambridgemichael kauffmandirector cambridgemichael kauffmandirector cambridgemichael kauffmandirector cambridgemichael kauffmandirector cambridgecurtis t keithsenior vp discovery bostoncurtis t keithsenior vp research cambridgecurtis t keithsvp research cambridgerobert e keith jrwaynegregory kopchinskyrowaytonmark n lampertchicagojan lessemexecutive vp  cmo bostonjan lessemexecutive vp  cmo cambridgelivzon mabpharm incgongbei zhuhai guangdongcorrigan markcambridger eric mcallistersenior vp clinical development bostonjulie mchughdirector chadds fordjulie mchughdirector bostonkauffman michaelcambridgechristopher mollerdirector waynemontreux equity partners iv lpsan franciscomontreux equity partners iv lp owner san franciscomontreux equity partners v lpsan franciscomontreux equity partners v lpsan franciscompm asset management investors  bviii llcbostonmpm asset management llcbostonmpm bioventures iii gmbh  co beteiligungs kgbostonmpm bioventures iii gp lpbostonmpm bioventures iii lpbostonmpm bioventures iii llc owner bostonmpm bioventures iii parallel fund lpbostonmpm bioventures iiiqp lpbostonamit munshichief executive officer bostonwilliam j osheadirector cambridgewilliam j osheadirector cambridgewilliam j osheadirector cambridgerichard f popsbostonrichard f popsdirector cambridgerichard f popsdirector cambridgejohn randlecambridgejohn randlesvp commercial development cambridgejustin a renzcambridgejustin a renzsvp  chief financial officer cambridgejustin a renzsvp  cfo cambridgejustin a renzevp cfo  treasurer cambridgehartley t richardsondirector cambridgehartley t richardsondirector cambridgehartley t richardsondirector cambridgescott m rocklagedirector lincolnscott m rocklagebostonscott m rocklagedirector bostonseth rudnickdirector bostonguy m russorowaytonguy m russorowaytoncrawford sallycambridgeandrew j schwabmenlo parkandrew j schwabmenlo parkkim sethchief business officer bostonthomas a sheachief financial officer bostonnicholas j simon iiibostonterrance p snutchsvp  chief scientific officer cambridgeterrance p snutchsvp  cso cambridgemichael steinmetzbostonstonehenge llcrowaytonrobert ticktingeneral counsel bostontl ventures v interfund lpwaynetl ventures v llcwaynetl ventures v lp owner waynetl ventures v management lpwaynefoley toddcambridgetpg group holdings sbs advisors inc owner fort worthtpg group holdings sbs advisors incfort worthaurentz vincentchief business officer bostonoshea wcambridgewaubeeka llcrowaytonkurt wheelerbostonhunter williamcambridgec eugene wrightsvp  chief dev officer cambridgec eugene wrightdirector cambridgemichael wyandpresident and coo bostoneric a youngrowaytoneric a young owner rowaytonpersons related to biotechnology value fund ii lp  chemocentryx incnamepositioncitypetrus bekkerchief medical officer mountain viewbiotechnology value fund l pbiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilbvf incilchicagobvf incilchicagobvf investments llcbvf investments llcchicagobvf investments llcchicagobvf partners l pil owner bvf partners l pil owner chicagobvf partners l pilchicagomarkus j cappelchief bus officer  treasurer mountain viewisrael charosvp research mountain viewannemarie duliegeevp chief of strategic dev mountain viewthomas a edwardsdirector mountain viewjoseph m feczkodirector new yorkjoseph m feczkodirector mountain viewplc glaxosmithkline owner brentford middlesexrishi guptadirector mountain viewsamuel d isalynew yorksamuel d isalynew yorkjuan c jaensvp drug discovery  cso mountain viewsusan m kanayaevp cfo and sec haywardsusan m kanayasvp finance cfo and sec mountain viewira kleindirector mountain viewmark n lampertsan franciscomark n lampertchicagomark n lampertchicagoroger c lucasdirector north oaksroger c lucasdirector mountain viewhenry a mckinnelldirector orbimed advisors llcnew yorkorbimed advisors llc owner new yorkorbimed capital gp i llcnew yorkorbimed capital gp i llcnew yorkorbimed capital llcnew yorkorbimed capital llcnew yorkgeoffrey m parkerdirector carlsbadgeoffrey m parkerdirector mountain viewedward penhoetdirector san franciscoedward penhoetdirector san franciscothomas j schallpresident and ceo mountain viewrajinder singhsvp research mountain viewtechne corp mn owner minneapolisjames l tyreedirector abbott parkjames l tyreedirector mountain viewpersons related to biotechnology value fund ii lp  celera corpnamepositioncitypaul d aratasvp hr  administration alamedarichard h ayersdirector alamedajeanluc belingarddirector alamedabiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner chicagobvf partners l pilchicagobvf x llcchicagobvf x llcchicagougo d deblasisvp chief financial officer alamedawilliam g greendirector alamedachristopher m hallchief business officer alamedapeter barton huttdirector alamedajoel r jungvp cfo  treasurer alamedamark n lampertchicagomark n lampertchicagovictor leevp cipc  asst sec alamedamichael w mercersenior vp berkeley heartlab alamedaalfred g merriweathersvp chief financial officer alamedascott milstensvp gnrl counsel  corp sec alamedagail k naughtondirector alamedakathy ordonezceo and director alamedaquest diagnostics inc owner madisonwayne i roedirector alamedabennett m shapirodirector alamedastacey r siassvp bus dev  strategic plann alamedaspark acquisition corpmadisonthomas j whitesvp chief scientific officer alamedamichael a zoccolisvp products group alamedapersons related to biotechnology value fund ii lp  abbott biotherapeutics corpnamepositioncitylaboratories abbott owner abbott parkamber acquisition incabbott parkbaupost group llcma owner bostonbiotechnology value fund l pchicagobiotechnology value fund l pchicagobvf incilchicagobvf incilchicagobvf investments llcchicagobvf investments llcchicagobvf partners l pil owner chicagobvf partners l pilchicagoherb crosscorp controllerprin acctg off redwood cityherb crossvp of financeprin acctg off redwood cityherb crossvp of finance redwood citykurt von emsterdirector redwood citykurt von emsterdirector redwood citybradford s goodwindirector redwood citybradford s goodwindirector redwood citybradford s goodwindirector redwood cityandrew guggenhimesvp  cfo redwood cityandrew guggenhimesvp  cfo redwood cityandrew guggenhimesvp  cfo redwood cityfaheem hasnainpresident  ceo redwood cityfaheem hasnainpresident  ceo redwood cityfaheem hasnainpresident  ceo redwood citymaninder horavp prod ops  quality redwood citymaninder horavp prod ops  quality redwood citymaninder horavp prod ops  quality redwood cityhoyoung huhdirector redwood cityhoyoung huhdirector redwood cityseth a klarmanbostonseth a klarmanbostonseth a klarmanbostonmark n lampertchicagomark n lampertchicagoted llanasvp comml  corp dev redwood cityted llanasvp comml  corp dev redwood cityted llanadvp comml  corp dev redwood citygary a lyonsdirector redwood citygary a lyonsdirector redwood citygary a lyonsdirector redwood citymark anthony mccamishsr vp  chief medical officer redwood citydavid ross parkinsondirector redwood citydavid ross parkinsondirector redwood citydavid ross parkinsondirector redwood citymark rolfesr vice pres and cso redwood citymark rolfesr vice pres and cso redwood citysak corpbostonsak corpbostonfrancis willard sarenavp gen counsel  secy redwood cityfrancis willard sarenavp gen counsel  secy redwood cityfrancis willard sarenavp gen counsel  secy redwood cityjaisim shahredwood city potentially same personnamecitycountrybiotechnology value fund ii lpbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpsan franciscocabiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpchicagoilbiotechnology value fund ii lpsan franciscoca   biotechnology value fund lp et al v merck  co inc search advanced search take a free trial  sign in close law indepth law uk adv search  platform tools browse all sections banking bankruptcy class action competition employment energy expert analysis insurance intellectual property product liability securities rankings laws mvps glass ceiling report global  law  diversity snapshot practice group partner rankings practice groups of the year pro bono firms of the year rising stars trial aces site menu join the law team search legal jobs learn more about law read testimonials contact law sign up for our newsletters site map help june   biotechnology value fund lp et al v merck  co inc track this case case number cv court new jersey nature of suit other statutory actions judge peter g sheridan firms lieff cabraser companies merck  co inc sectors  industries healthcare major view recent docket activity reflects complaints answers motions orders and trial notes entered from jan  additional or older documents may be available in pacer parties to view the parties register now try law free for seven days already a subscriber click here to login × already have access click here to login get instant access to the onestop news source for business lawyers register now get instant access to the onestop news source for business lawyers email professional email required first name last name please note a verification email will be sent to your address before you can access your trial password at least  characters required confirm password select at least one primary interest aerospace  defense appellate asset management automotive banking bankruptcy california capital markets class action commercial contracts competition consumer protection corporate cybersecurity  privacy delaware employment energy environmental financial services uk florida food  beverage government contracts health hospitality illinois immigration insurance insurance uk intellectual property international arbitration international trade law in depth legal ethics life sciences media  entertainment medical malpractice mergers  acquisitions native american new jersey new york pennsylvania private equity product liability project finance public policy real estate retail  e commerce securities sports tax technology telecommunications texas transportation trials white collar register already have access email password forgot your password remember login sign in microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft united states personal investing trowepricecom personal investing workplace retirement institutional investor institutional consultant financial advisorintermediary recordkeeping sponsorconsultant log out log in open an account about us help my accounts portfolio transactions statements  documents profile mutual funds daily prices historical performance dividend distributions mutual fund research tool morningstar  and star rated funds stock funds bond funds target date funds asset allocation funds money market funds prospectuses  reports retirement ira rollover ira retirement planning required minimum distributions small business retirement plans b plans planning  research advice investing  asset allocation planning retirement planning college planning tax planning estate planning research  analysis t rowe price insights planning  resources charitable giving products  services activeplus portfolios college savings plans non retirement accounts private asset management select client services advisory planning services brokerage investor centers t rowe price value fund trvlx home  mutual funds t rowe price value fund print this page email this page text size new quarterly fund fact sheet now available ticker symbol trvlx fund status open to new retail investors    open to subsequent retail investments snapshot objective performance composition management expensesminimums compare fund snapshot quick stats current nav as of   nav change  daily ytd return as of   nav  month lowhigh    net assets as of   million morningstar ratings as of  overall  year  year  year morningstar rated the value fund among    and  large value funds for the overall rating and the   and year periods as applicable ending  respectively the overall morningstar rating for a managed product is derived from a weighted average of the performance figures associated with its three five and year if applicable morningstar rating metrics the weights are  threeyear rating for  months of total returns  fiveyear rating threeyear rating for  months of total returns and  year rating fiveyear rating threeyear rating for  or more months of total returns while the year overall star rating formula seems to give the most weight to the year period the most recent threeyear period actually has the greatest impact because it is included in all three rating periods performance comparison as of  this chart shows the value of a hypothetical  investment in the fund over the past  years or since its inception for funds lacking year records the result is compared with benchmarks which may include a broadbased market index and a peer group average or index market indexes do not include expenses which are deducted from fund returns as well as mutual fund averages and indexes benchmark definitions  the morningstar rating for funds or star rating is calculated for managed products including mutual funds variable annuity and variable life subaccounts exchangetraded funds closedend funds and separate accounts with at least a threeyear history exchangetraded funds and openended mutual funds are considered a single population for comparative purposes it is calculated based on a morningstar riskadjusted return measure that accounts for variation in a managed products monthly excess performance placing more emphasis on downward variations and rewarding consistent performance the top  of products in each product category receive  stars the next  receive  stars the next  receive  stars the next  receive  stars and the bottom  receive  star the overall morningstar rating for a managed product is derived from a weighted average of the performance figures associated with its three five and year if applicable morningstar rating metrics the weights are  threeyear rating for  months of total returns  fiveyear rating threeyear rating for  months of total returns and  year rating fiveyear rating threeyear rating for  or more months of total returns while the year overall star rating formula seems to give the most weight to the year period the most recent threeyear period actually has the greatest impact because it is included in all three rating periods source for morningstar data   morningstar inc all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information past performance is no guarantee of future results average annual total returns and benchmarks as of  benchmark definitions investment objective the fund seeks to provide longterm capital appreciation by investing in common stocks believed to be undervalued income is a secondary objective average annual total returns    monthend  quarterend   year    years    years    years   since inception   inception date september   gross expense ratio  net expense ratio  waiver type na limitation expires na current performance may be lower or higher than the quoted past performance which cannot guarantee future results share price principal value and return will vary and you may have a gain or loss when you sell your shares  average annual total return figures include changes in principal value reinvested dividends and capital gain distributions for funds less than one year old the since inception return figure is not annualized and represents an aggregate total return  the gross expense ratio reflects the fund expenses as stated in the fee table of the funds prospectus prior to the deduction of any waiver or reimbursement the net expense ratio reflects fund expenses after the deduction of any waiver or reimbursement if a fund has an active contractual expense ratio limitation the expiration date is shown below the gross and net expense ratio values above expense ratios are as of the most recent prospectus open an account transact  trade viewupdate accounts help center find a fund select fund by name africa  middle east  i cl africa  middle east fund asia opportunities asia opportunities  i cl balanced balanced  i cl blue chip growth blue chip growth  i cl california taxfree bond california taxfree bond  i cl california taxfree money california taxfree money  i cl capital appreciation capital appreciation  i cl capital opportunity capital opportunity  i cl cash reserves corporate income corporate income  i cl credit opportunities credit opportunities  i cl diversified midcap growth diversified midcap growth  i cl dividend growth dividend growth  i cl dynamic global bond dynamic global bond  i cl em mkts corporate bond  i cl em mkts local currency bond  i cl emerging europe emerging europe  i cl emerging markets bond emerging markets bond  i cl emerging markets corporate bond emerging markets local currency bond emerging markets stock emerging markets stock  i cl emerging markets value stock emerging markets value stock  i cl equity income equity income  i cl equity index  equity index   i cl european stock european stock  i cl extended equity market index financial services financial services  i cl floating rate floating rate  i cl georgia taxfree bond georgia taxfree bond  i cl global allocation global allocation  i cl global consumer global growth stock global growth stock  i cl global high income bond global high income bond  i cl global industrials global industrials  i cl global multisector bond global multisector bond  i cl global real estate  i cl global real estate fund global stock global stock  i cl global technology  i cl global technology fund gnma gnma  i cl government money government money  i cl growth  income growth  income  i cl growth stock growth stock  i cl health sciences health sciences  i cl high yield high yield  i cl inflation protected bond inflation protected bond  i cl intermediate taxfree high yield intermediate taxfree hy  i cl international bond international bond  i cl international concentrated eq  i cl international concentrated equity international discovery international discovery  i cl international equity index international stock international stock  i cl international value equity international value equity  i cl japan japan  i cl latin america latin america  i cl limited duration inflation focused bd lmtd duration infl focused bd  i cl maryland shortterm taxfree bond maryland shortterm txfr bnd  i cl maryland taxfree bond maryland taxfree bond  i cl maryland taxfree money maryland taxfree money  i cl media  telecommunications media  telecommunications  i cl midcap growth midcap growth  i cl midcap value midcap value  i cl new america growth new america growth  i cl new asia new asia  i cl new era new era  i cl new horizons new horizons  i cl new income new income  i cl new jersey taxfree bond new jersey taxfree bond  i cl new york taxfree bond new york taxfree bond  i cl new york taxfree money new york taxfree money  i cl overseas stock  i cl overseas stock fund personal strategy balanced personal strategy balanced  i cl personal strategy growth personal strategy growth  i cl personal strategy income personal strategy income  i cl qm global equity qm global equity  i cl qm us small  midcap core eq  i cl qm us small  midcap core equity qm us smallcap growth equity qm us smallcap growth equity  i cl qm us value equity qm us value equity  i cl real assets real assets  i cl real estate real estate  i cl retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement balanced fund retirement balanced i  i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement i   i cl retirement income  science  technology science  technology  i cl shortterm bond shortterm bond  i cl smallcap stock smallcap stock  i cl smallcap value smallcap value  i cl spectrum growth spectrum income spectrum international summit municipal income summit municipal intermediate summit municipal money market target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl target  target   i cl taxefficient equity  i cl taxefficient equity fund taxexempt money taxexempt money  i cl taxfree high yield taxfree high yield  i cl taxfree income taxfree income  i cl taxfree shortintermediate taxfree shortintermediate  i cl total equity market index total return total return  i cl us bond enhanced index us high yield us high yield  i cl us largecap core  i cl us largecap core fund us treasury intermediate us treasury intermediate  i cl us treasury longterm us treasury longterm  i cl us treasury money us treasury money  i cl ultra shortterm bond ultra shortterm bond  i cl value value  i cl virginia taxfree bond virginia taxfree bond  i cl select by ticker symbol gtfbx mdxbx njtfx nytxx otcfx otiix pbdix pccox pctxx pdgix pexmx pglox pgmsx pgtix pieqx pnaix pnsix pomix ppipx prafx pramx prasx prcix prcnx prcox prcpx prdgx prdmx prdsx prefx preix prelx premx presx prfdx prfhx prfrx prfsx prgfx prgix prgmx prgsx prgtx prhix prhsx prhyx pridx prihx prijx prikx prinx pripx prisx pritx priux prjix prjpx prkix prlax prmdx prmsx prmtx prnex prnhx prnyx prpix prrxx prscx prsgx prsix prsmx prsnx prsvx prtax prtix prtxx prufx pruix prulx pruux prvax prvix prwax prwbx prwcx prxax prxcx prxex prxix przix psilx ptexx ptkix pttfx ptyix rbaix rclix reipx revix rggix ricix rjaix rlaix rpbax rpeix rpgax rpgex rpgix rpgrx rpibx rpiex rpihx rpisx rpmgx rpoix rpsix rptfx rptix rpttx tbcix tbgax tbsix tcbxx tcfex tcrrx tecix teefx teimx terxx teuix tfaix tfbix tfbvx tfhax tfifx tfilx tfrrx tgafx tgipx tgtix thisx ticcx tiddx tiipx tirgx tirrx tmdxx toorx torfx tpgpx tppax tqaix tqgex tqgix tqmvx tqsix tqsmx tqvix traix tramx traox trarx trasx trbcx trbfx trbrx trbux trecx tremx trffx trfgx trfox trfwx trgax trglx trgrx trgxx trhrx trigx trjix trlax trldx trmcx trmix trmux trnex trnxx troix trosx trpax trpbx trpcx trpdx trpfx trphx trpix trpjx trpkx trplx trpmx trpnx trppx trptx trrax trrbx trrcx trrdx trrex trrfx trrgx trrhx trrix trrjx trrkx trrlx trrmx trrnx trrox trrtx trrux trrvx trrwx trsgx trstx trsxx trtfx trtix trulx trvlx trvvx trxrx tryix tscxx tsnix tteex ttgxx ttmix ttoix ttrtx ttsix tturx tuhix tuhyx twnxx twrrx more fund information download a prospectus download a semiannual report download an annual report download statement of additional information yearend dividend distributions yearend tax considerations dividend distribution dates   related links also available to certain investors as a lower cost i class mutual fund our mission is simple help clients around the world achieve their longterm investment goals connect with us facebook twitter youtube linkedin company overview responsibility careers investor relations press releases site map privacy policy terms of use security measures legal information customer agreement feedback mobile solutions contact us the mutual funds referred to in this website are offered and sold only to persons residing in the united states and are offered by prospectus only the prospectuses include investment objectives risks fees expenses and other information that you should read and consider carefully before investing download a prospectus fri jul   edt  all rights reserved t rowe price investment services inc distributor t rowe price mutual funds t rowe price invest with confidence and the bighorn sheep design are trademarks of t rowe price group inc all other trademarks are the property of their respective owners morningstar  and star rated funds  mutual funds  t rowe price  t rowe price home mutual funds morningstar  and star rated funds over  of our funds have earned  or star overall morningstar ratings as of  invest now call us at  download a prospectus morningstar  and star rated funds stock funds us stock funds international and global stock funds bond funds us bond funds international and global bond funds target date funds retirement funds target funds income funds asset allocation funds money market funds find a fund browse all t rowe price mutual funds many of our mutual funds earn morningstar’s highest ratings morningstar  and star rated funds because of our disciplined approach to investing morningstar a leader in independent investment research recognizes many of our mutual funds with its highest ratings in the funds respective categories over  of our funds have earned  or star overall morningstar ratings as of  morningstar uses a star system to rate mutual funds based on their riskadjusted returns five stars is the highest while one star is the lowest rating only the top  of all funds of the   get  stars and  get  stars are awarded morningstars  or star rating by comparison as of   of  of our rated funds investor class only received an overall rating of  or  stars​ past performance cannot guarantee future results view all  and star rated funds explore morningstar  and star rated funds fund nameticker morningstarcategory overall morningstarrating™ no offunds incategory riskrewardpotential fund name ticker morningstar category overall morningstar rating™ no of funds in category riskreward potential compare morningstar  and star rated funds find a fund browse all t rowe price mutual funds t rowe price insightsreg markets  economy monthly market review stay informed about global economic developments and our perspective on market conditions read more   source t rowe price markets  economy global markets weekly update keep uptodate on our views on developments in global capital markets read more july    source t rowe price all mutual funds are subject to market risk including possible loss of principal morningstar gives its best ratings of  or  stars to the top  of all funds of the   get  stars and  get  stars based on their riskadjusted returns the overall morningstar rating™ is derived from a weighted average of the performance figures associated with a funds   and year if applicable morningstar rating™ metrics as of   of  of our rated funds investor class only received an overall rating of  or  stars the morningstar ratingtm for funds or star rating is calculated for funds with at least a threeyear history exchangetraded funds and openended mutual funds are considered a single population for comparative purposes it is calculated based on a morningstar riskadjusted return measure that accounts for variation in a managed products monthly excess performance placing more emphasis on downward variations and rewarding consistent performance the top  of products in each product category receive  stars the next  receive  stars the next  receive  stars the next  receive  stars and the bottom  receive  star source for morningstar data  morningstar inc all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information past performance is no guarantee of future results this chart displays relative risk of each us mutual fund listed using standard deviation of returns those values are provided in the bars at the top of the chart methodology we evaluate the standard deviation and its resulting placement within a specific riskreturn category on an annual basis a fund is generally placed in a riskreturn category based on the year standard deviation of its performance if a fund is less than  years old the actual fund performance history is supplemented with the primary prospectus benchmark history to obtain a full year history or longest time period available up to  years for an asset allocation fund with less than  years of performance history substrategy returns are used when a substrategy is less than  years old the actual substrategy performance history is supplemented with benchmark history to obtain a full year history or longest time period available up to  years risk return categories overlap a fund with a standard deviation in the overlap between two categories denoted by a plus  is placed so that its risk categorization is better aligned with anticipated return characteristics an investor may experience going forward at the discretion of t rowe price when a fund has a cashlike benchmark denoted by a double plus  its standard deviation is estimated using only available fund returns if the fund is less than  years old benchmark returns are not used to obtain a full year history because they would artificially suppress the volatility estimate all investments are subject to market risk including the possible loss of principal standard deviation of returns a measure of price volatility is one measure of risk please consult the funds’ prospectuses for a more complete discussion of the funds’ risks  california taxfree money fund capital appreciation fund equity income fund global allocation fund global industrials fund gnma fund inflation protected bond fund international bond fund international stock fund japan fund limited duration inflation focused bond fund new era fund personal strategy balanced fund personal strategy income fund qm global equity fund qm global equity fund qm us value equity fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund retirement  fund shortterm bond fund spectrum international fund summit municipal intermediate fund target  fund target  fund target  fund target  fund target  fund taxfree shortintermediate fund total equity market index fund ultra shortterm bond fund  global unconstrained bond fund mutual funds retirement and investment services  t rowe price  home mutual funds retirement and investment services introducing t rowe price®  activeplus portfolios save time with a diversified portfoliopowered by our experts get started my account   remember user name log in log in forgot user name register for online access  open an account mutual funds we offer over  noload mutual funds to address your specific investing needs see all mutual funds rollover iras changing jobs or planning for retirement our specialists make rolling over your k account easy learn more ira plan for retirement with the help of a roth ira or traditional ira learn more see all products and services   find lowcost mutual funds to help you achieve your financial goals search mutual funds  noload mutual funds providing a broad set of opportunities historical performance daily prices download a prospectus mutual fund categories we offer a full range of investment strategies across multiple asset classes capitalizations sectors and styles fund type number available stock funds  asset allocation funds  money market funds  target date funds  bond funds  see all mutual funds   over  of our mutual funds beat their year lipper average as of  learn more   t rowe price insights® access our latest investment thinking information on retirement planning and perspectives on the markets asset allocation an inside look at t rowe price® activeplus portfolios july   retirement planning  key ingredients for retirement planning july   markets  economy quarterly market review june   see all articles   ready to get started open an account or call  view firms background on finras brokercheck t rowe price mutual funds are subject to ongoing management fees and may be subject to redemption fees an ira may be subject to an annual fee and a fee may be assessed when an ira is closed see prospectus for details the mutual funds referred to in this website are offered and sold only to persons residing in the united states and are offered by prospectus only the prospectuses include investment objectives risks fees expenses and other information that you should read and consider carefully before investing morningstar gives its best ratings of  or  stars to the top  of all funds of the   get  stars and  get  stars based on their riskadjusted returns the overall morningstar rating™ is derived from a weighted average of the performance figures associated with a funds   and year if applicable morningstar rating™ metrics as of   of  of our rated funds investor class only received an overall rating of  or  stars the morningstar ratingtm for funds or star rating is calculated for funds with at least a threeyear history exchangetraded funds and openended mutual funds are considered a single population for comparative purposes it is calculated based on a morningstar riskadjusted return measure that accounts for variation in a managed products monthly excess performance placing more emphasis on downward variations and rewarding consistent performance the top  of products in each product category receive  stars the next  receive  stars the next  receive  stars the next  receive  stars and the bottom  receive  star source for morningstar data  morningstar inc all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information past performance is no guarantee of future results  of our  mutual funds had a year track record as of  includes all share classes and excludes funds used in insurance products  of these  funds beat their lipper averages for the year period  of    of   of   of t rowe price funds outperformed their lipper average for the   and year periods ended  respectively calculations are based on cumulative total return not all funds outperformed for all periods source for data lipper inc  of our  retirement funds had a year track record as of  includes all share classes  of these  funds beat their lipper averages for the year period  of   of  and  of  of the retirement funds outperformed their lipper average for the   and year periods ended  respectively calculations are based on cumulative total return not all funds outperformed for all periods source for data lipper inc source lipper inc  of  funds excluding institutional and bank institutional funds as defined by lipper more than  months old had expense ratios below their lipper averages based on fiscal yearend data available as of  the principal value of the retirement funds is not guaranteed at any time including at or after the target date which is the approximate year an investor plans to retire assumed to be age  and likely stop making new investments in the fund if an investor plans to retire significantly earlier or later than age  the funds may not be an appropriate investment even if the investor is retiring on or near the target date the funds’ allocations among a broad range of underlying t rowe price stock and bond funds will change over time the funds emphasize potential capital appreciation during the early phases of retirement asset accumulation balance the need for appreciation with the need for income as retirement approaches and focus on supporting an income stream over a longterm postretirement withdrawal horizon the funds are not designed for a lumpsum redemption at the target date and do not guarantee a particular level of income the funds maintain a substantial allocation to equities both prior to and after the target date which can result in greater volatility over shorter time horizons x you are using an unsupported browser version that might prevent you from accessing certain features on our site   we suggest clicking an icon below to download a supported browser version     google chrome mozilla firefox internet explorer safari  page not found page not found we apologize for any inconvenience but we are unable to locate the page you requested this could be due to either of the reasons below if you manually entered the url please make sure it is correct check that the capitalization matches that all words are spelled correctly and that all the punctuation like periods  and slashes  are correctly placed be sure that you are using the forward slash  and not the backward slash  remember there are no spaces in urls if you have bookmarked this page this page may have been renamed moved or deleted please return to our homepage and reset your bookmarks biotech bull  bear x etf  labu labd  direxion brzu daily msci brazil bull x shareschad daily csi  china a share bear x shareschau daily csi  china a share bull x sharesclaw daily homebuilders  supplies bear x sharescom direxion auspice broad commodity strategy etfcure daily healthcare bull x sharescweb daily csi china internet index bull x sharesdfen daily aerospace  defense bull x sharesdpk daily msci developed markets bear x sharesdpst daily regional banks bull x sharesdrip daily sp oil  gas exp  prod bear x sharesdrn daily msci real estate bull x sharesdrv daily msci real estate bear x sharesdull daily silver miners index bear x sharesdusl daily industrials bull x sharesdust daily gold miners index bear x sharesdxcbx direxion indexed cvt strategy funddxcix direxion indexed commodity strategy fund – instdxctx direxion indexed commodity strategy fund – adxelx monthly emerging markets bull x funddxhlx monthly china bull x funddxhyx monthly high yield bull x funddxklx monthly  year treasury bull x funddxksx monthly  year treasury bear x funddxltx monthly  year treasury bull x funddxmax direxion indexed managed futures strategy fund – adxmcx direxion indexed managed futures strategy fund – cdxmix direxion indexed managed futures strategy fund – instdxnlx monthly nasdaq bull x funddxnsx monthly nasdaq bear x funddxqlx monthly nasdaq bull x funddxrlx monthly small cap bull x funddxrsx monthly small cap bear x funddxscx direxion indexed commodity strategy fund – cdxslx monthly sp  bull x funddxssx monthly sp  bear x funddxstx monthly  year treasury bear x funddzk daily msci developed markets bull x sharesedc daily msci emerging markets bull x sharesedz daily msci emerging markets bear x shareserx daily energy bull x sharesery daily energy bear x shareseryy daily energy bear x shareseufl daily msci european financials bull x shareseufs daily msci european financials bear x shareseurl daily ftse europe bull x shareseuxl daily euro stoxx  bull x sharesfas daily financial bull x sharesfaz daily financial bear x sharesfazz daily financial bear x sharesgasl daily natural gas related bull x sharesgasx daily natural gas related bear x sharesgush daily sp oil  gas exp  prod bull x shareshakk daily cyber security  it bull x shareshcyax direxion hilton tactical income fund – a shareshcycx direxion hilton tactical income fund – c shareshcyix direxion hilton tactical income fund – institutionalhydd daily high yield bear x sharesibln direxion ibillionaire index etfindl daily msci india bull x sharesjdst daily junior gold miners index bull x sharesjdst daily junior gold miners index bear x sharesjpnl daily msci japan bull x sharesknow direxion all cap insider sentiment shareskoru daily msci south korea bull x shareslabd daily sp biotech bear x shareslabs daily sp biotech bear x shareslabu daily sp biotech bull x shareslbj daily latin america bull x sharesllsc daily small cap bull x sharesllsp daily sp  bull x sharesmelt daily gold miners index bear x sharesmexx daily msci mexico bull x sharesmidu daily mid cap bull x sharesmidz daily mid cap bear x sharesnail daily homebuilders  supplies bull x sharesnugt daily gold miners index bull x sharespemvx evolution managed fundsqqqe direxion nasdaq equal weighted index sharesretl daily retail bull x sharesrusl daily russia bull x sharesruss daily russia bear x sharessagg daily total bond market bear x sharesshny daily silver miners index bull x sharessick daily healthcare bear x sharessmll daily small cap bull x sharessoxl daily semiconductor bull x sharessoxs daily semiconductor bear x sharesspdn daily sp  bear x sharessplz daily consumer staples bear x sharesspuu daily sp  bull x sharesspxl daily sp  bull x sharesspxs daily sp  bear x sharestecl daily technology bull x sharestecs daily technology bear x sharestecz daily technology bear x sharestmf daily  year treasury bull x sharestmv daily  year treasury bear x sharestna daily small cap bull x sharestpor daily transportation bull x sharestybs daily  year treasury bear x sharestyd daily  year treasury bull x sharestyns daily  year treasury bear x sharestyo daily  year treasury bear x sharestza daily small cap bear x sharesutlz daily utilities bear x sharesutsl daily utilities bull x shareswdrw daily regional banks bear x sharesyang daily ftse china bear x sharesyinn daily ftse china bull x shareszmlp direxion zacks mlp high income index shares direxion daily sp biotech bull and bear x shares fund symbol labu daily target  intraday indicative value labuiv bloomberg index spsibitr cusip k isin usk expense ratio grossnet     inception date may   fund symbol labd daily target  intraday indicative value labdiv bloomberg index spsibitr cusip k isin usk expense ratio grossnet     inception date may   overview the direxion daily sp biotech bull and bear x shares seek daily investment results before fees and expenses of  or  of the inverse or opposite of the performance of the sp biotechnology select industry index there is no guarantee the funds will meet their stated investment objectives these leveraged etfs seek a return that is  or  of the return of their benchmark index for a single day the funds should not be expected to provide three times or negative three times the return of the benchmark’s cumulative return for periods greater than a day labu labd fact sheet etf guide labu prospectus labd prospectus premium discount daily holdings download labu daily holdings csv download labd daily holdings csv daily holdings labu     daily sp biotech bull x shares trade date     shares outstanding  stock ticker security description shares price market value — bank of new york cash reserve    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — goldman finl sq trsry inst     — goldman finl sq trsry inst     — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    xbi spdr sp biotech etf    labd     daily sp biotech bear x shares trade date     shares outstanding  stock ticker security description shares price market value — bank of new york cash reserve    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — dreyfus govt cash mgmt    — goldman finl sq trsry inst     — goldman finl sq trsry inst     — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    — sp biotechnology select industry index swap    strategy  benefits key benefits you know that trading is different than investing but the opportunity to take advantage of shortterm trends is only won if you get the direction right whether you’re a bull or a bear direxion is with you our leveraged etfs are powerful tools built to help you magnify your shortterm perspective with daily x leverage go where there’s opportunity with bull and bear funds for both sides of the trade and stay agile – with liquidity to trade through rapidly changing markets leveraged and inverse etfs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage they seek daily goals and should not be expected to track the underlying index over periods longer than one day they are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments target index the sp biotechnology select industry index spsibitr is provided by standard  poor’s and includes domestic companies from the biotechnology industry the index is designed to measure the performance of the biotechnology subindustry based on the global industry classification standards gics one cannot directly invest in an index index top ten holdings  clovis oncology inc  exelixis inc  kite pharma inc  alexion pharmaceuticals inc  celgene corp  alnylam pharmaceuticals inc  gilead sciences inc  sarepta therapeutics inc  bioverativ inc  exact sciences corp  index sector weightings  medicalbiomedicalgenetics  medicaldrugs  therapeutics  medicalgeneric drugs  diagnostic kits  medical products  diagnostic equipment  drug delivery systems  index data as of  source bloomberg index sector weightings and top holdings are subject to change tax reporting supplemental tax documents  – ordinary income from us government obligations labd pricing and performance pricing and performance nav and market price information as of july   line chart shows pricing trend over the last  days fund symbol labu net asset value nav  nav   change   change  market price closing  market   change   change  premium  discount   change from last day trading fund symbol labd net asset value nav  nav   change   change  market price closing  market   change   change  premium  discount   change from last day trading monthly quarterly as of june   as of june   labu daily sp biotech bull x shares m  m  ytd  y  since inception inception date expense ratio  gross  net  m  m  ytd  y  since inception inception date expense ratio  gross  net  nav          market close      nav          market close      spsibitr benchmark index        labd daily sp biotech bear x shares m  m  ytd  y  since inception inception date expense ratio  gross  net  m  m  ytd  y  since inception inception date expense ratio  gross  net  nav          market close      nav          market close      spsibitr benchmark index         the net expense ratio includes management fees other operating expenses and acquired fund fees and expenses if acquired fund fees and expenses were excluded the net expense ratio would be  the funds’ adviser rafferty asset management llc “rafferty” has entered into an operating expense limitation agreement with each fund under which rafferty has contractually agreed to cap all or a portion of its management fee andor reimburse each fund for other expenses through september   to the extent that the fund’s total annual fund operating expenses exceed  of the fund’s daily net assets other than the following taxes swap financing and related costs acquired fund fees and expenses dividends or interest on short positions other interest expenses brokerage commissions and extraordinary expenses if these expenses were included the expense ratio would be higher the performance data quoted represents past performance past performance does not guarantee future results the investment return and principal value of an investment will fluctuate an investor’s shares when redeemed may be worth more or less than their original cost current performance may be lower or higher than the performance quoted returns for performance under one year are cumulative not annualized for the most recent monthend performance please visit the funds website at direxioninvestmentscom shortterm performance in particular is not a good indication of the fund’s future performance and an investment should not be made based solely on returns because of ongoing market volatility fund performance may be subject to substantial shortterm changes for additional information see the fund’s prospectus distributions distributions labu daily sp biotech bull x shares there are no recent distributions available for this fund labd daily sp biotech bear x shares there are no recent distributions available for this fund related reading knowledge related education articles and insights etf market pricing etf market prices are the prices at which investors buy or sell shares of an etf in the secondary market while etfs are designed to trade in line with their intraday values during times of significant market volatility an etf’s market price may vary more widely from its intraday value etf liquidity – four rules to consider liquidity transparency realtime trading and relatively low management fees are the reason why etfs are becoming more and more popular learn about the four key characteristics that investors should better understand in order to trade them properly more articles like this